Olle Ringdén

Publications
CV
Public outreach and news

Articles

Article: CYTOTHERAPY. 2023;25(1):68-75

Immunomodulation by placenta-derived decidua stromal cells. Role of histocompatibility, accessory cells and freeze-thawing.

Sadeghi B; Witkamp M; Schefberger D; Arbman A; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2022;28(10):681-693

Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

Saliba RM; Alousi AM; Pidala J; Arora M; Spellman SR; Hemmer MT; Wang T; Abboud C; Ahmed S; Antin JH; Beitinjaneh A; Buchbinder D; Byrne M; Cahn J-Y; Choe H; Hanna R; Hematti P; Kamble RT; Kitko CL; Laughlin M; Lekakis L; MacMillan ML; Martino R; Mehta PA; Nishihori T; Patel SS; Perales M-A; Rangarajan HG; Ringdén O; Rosenthal J; Savani BN; Schultz KR; Seo S; Teshima T; van der Poel M; Verdonck LF; Weisdorf D; Wirk B; Yared JA; Schriber J; Champlin RE; Ciurea SO
Article: BLOOD ADVANCES. 2022;6(1):339-357

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.

Wieduwilt MJ; Metheny L; Zhang M-J; Wang H-L; Estrada-Merly N; Marks DI; Al-Homsi AS; Muffly L; Chao N; Rizzieri D; Gale RP; Gadalla SM; Cairo M; Mussetti A; Gore S; Bhatt VR; Patel SS; Michelis FV; Inamoto Y; Badawy SM; Copelan E; Palmisiano N; Kharfan-Dabaja MA; Lazarus HM; Ganguly S; Bredeson C; Diaz Perez MA; Cassaday R; Savani BN; Ballen K; Martino R; Wirk B; Bacher U; Aljurf M; Bashey A; Murthy HS; Yared JA; Aldoss I; Farhadfar N; Liu H; Abdel-Azim H; Waller EK; Solh M; Seftel MD; van der Poel M; Grunwald MR; Liesveld JL; Kamble RT; McGuirk J; Munker R; Cahn J-Y; Lee JW; Freytes CO; Krem MM; Winestone LE; Gergis U; Nathan S; Olsson RF; Verdonck LF; Sharma A; Ringdén O; Friend BD; Cerny J; Choe H; Chhabra S; Nishihori T; Seo S; George B; Baxter-Lowe LA; Hildebrandt GC; de Lima M; Litzow M; Kebriaei P; Hourigan CS; Abid MB; Weisdorf DJ; Saber W
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:963445

Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.

Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):993.e1-993.e8

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Orfali N; Zhang M-J; Allbee-Johnson M; Boelens JJ; Artz AS; Brunstein CG; McNiece IK; Milano F; Abid MB; Chee L; Diaz MA; Grunwald MR; Hematti P; Hsu J; Lazarus HM; Munshi PN; Prestidge T; Ringden O; Rizzieri D; Riches ML; Seo S; Solh M; Solomon S; Szwajcer D; Yared J; van Besien K; Eapen M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(11):923.e1-923.e12

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.

Metheny L; Callander NS; Hall AC; Zhang M-J; Bo-Subait K; Wang H-L; Agrawal V; Al-Homsi AS; Assal A; Bacher U; Beitinjaneh A; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Cairo M; Cerny J; DeFilipp Z; Perez MAD; Freytes CO; Ganguly S; Grunwald MR; Hashmi S; Hildebrandt GC; Inamoto Y; Kanakry CG; Kharfan-Dabaja MA; Lazarus HM; Lee JW; Nathan S; Nishihori T; Olsson RF; Ringdén O; Rizzieri D; Savani BN; Savoie ML; Seo S; van der Poel M; Verdonck LF; Wagner JL; Yared JA; Hourigan CS; Kebriaei P; Litzow M; Sandmaier BM; Saber W; Weisdorf D; de Lima M
Article: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2021;25(22):10554-10564

Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells.

Sadeghi B; Roshandel E; Pirsalehi A; Kazemi S; Sankanian G; Majidi M; Salimi M; Aghdami N; Sadrosadat H; Samadi Kochaksaraei S; Alaeddini F; Ringden O; Hajifathali A
Article: BONE MARROW TRANSPLANTATION. 2021;56(9):2108-2117

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Percival M-E; Wang H-L; Zhang M-J; Saber W; de Lima M; Litzow M; Kebriaei P; Abdel-Azim H; Adekola K; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bejanyan N; Bhatt V; Byrne M; Cahn J-Y; Castillo P; Chao N; Chhabra S; Copelan E; Cutler C; DeFilipp Z; Dias A; Diaz MA; Estey E; Farhadfar N; Frangoul HA; Freytes CO; Gale RP; Ganguly S; Gowda L; Grunwald M; Hossain N; Kamble RT; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Krem M; Lazarus HM; Lee JW; Liesveld JL; Lin R; Liu H; McGuirk J; Munker R; Murthy HS; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Passweg JR; Prestidge T; Ringdén O; Rizzieri DA; Rybka WB; Savoie ML; Schultz KR; Seo S; Sharma A; Solh M; Strair R; van der Poel M; Verdonck LF; Yared JA; Weisdorf D; Sandmaier BM
Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(21):2397-2409

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation.

Mayor NP; Wang T; Lee SJ; Kuxhausen M; Vierra-Green C; Barker DJ; Auletta J; Bhatt VR; Gadalla SM; Gragert L; Inamoto Y; Morris GP; Paczesny S; Reshef R; Ringdén O; Shaw BE; Shaw P; Spellman SR; Marsh SGE
Article: ORAL DISEASES. 2021;27(5):1217-1225

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis.

Garming Legert K; Ringdén O; Remberger M; Törlén J; Mattsson J; Dahllöf G
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2021;113(5):712-722

Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Ringdén O; Remberger M; Törlén J; Finnbogadottir S; Svahn B-M; Sadeghi B
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:774052

Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling.

Catar R; Moll G; Kamhieh-Milz J; Luecht C; Chen L; Zhao H; Ernst L; Willy K; Girndt M; Fiedler R; Witowski J; Morawietz H; Ringdén O; Dragun D; Eckardt K-U; Schindler R; Zickler D
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2020;26(10):1930-1936

Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.

Solomon SR; Martin AS; Zhang M-J; Ballen K; Bashey A; Battiwalla M; Baxter-Lowe LA; Brunstein C; Chhabra S; Perez MAD; Fuchs EJ; Ganguly S; Hardy N; Hematti P; McGuirk J; Peres E; Ringden O; Rizzieri D; Romee R; Solh M; Szwajcer D; van der Poel M; Waller E; William BM; Eapen M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(18):2062-2076

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Agrawal V; Ahmed I; Al-Homsi AS; Aljurf M; Antin JH; Askar M; Auletta JJ; Bhatt VR; Chee L; Chhabra S; Daly A; DeFilipp Z; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Hogan WJ; Inamoto Y; Martino R; Majhail NS; Marks DI; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Rangarajan HG; Ringden O; Saad A; Savani BN; Schoemans H; Seo S; Schultz KR; Solh M; Spitzer T; Storek J; Teshima T; Verdonck LF; Wirk B; Yared JA; Cahn J-Y; Weisdorf DJ
Article: HAEMATOLOGICA. 2020;105(5):1329-1338

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Lazaryan A; Dolan M; Zhang M-J; Wang H-L; Kharfan-Dabaja MA; Marks DI; Bejanyan N; Copelan E; Majhail NS; Waller EK; Chao N; Prestidge T; Nishihori T; Kebriaei P; Inamoto Y; Hamilton B; Hashmi SK; Kamble RT; Bacher U; Hildebrandt GC; Stiff PJ; McGuirk J; Aldoss I; Beitinjaneh AM; Muffly L; Vij R; Olsson RF; Byrne M; Schultz KR; Aljurf M; Seftel M; Savoie ML; Savani BN; Verdonck LF; Cairo MS; Hossain N; Bhatt VR; Frangoul HA; Abdel-Azim H; Malki MA; Munker R; Rizzieri D; Khera N; Nakamura R; Ringdén O; van der Poel M; Murthy HS; Liu H; Mori S; De Oliveira S; Bolaños-Meade J; Elsawy M; Barba P; Nathan S; George B; Pawarode A; Grunwald M; Agrawal V; Wang Y; Assal A; Caro PC; Kuwatsuka Y; Seo S; Ustun C; Politikos I; Lazarus HM; Saber W; Sandmaier BM; De Lima M; Litzow M; Bachanova V; Weisdorf D; Acute Leukemia Committee of the CIBMTR
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2020;111(4):591-594

Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells.

Sadeghi B; Ersmark B; Moretti G; Mattsson J; Ringdén O
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2020;13(2):293-300

Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.

El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:567210

Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.

Ringdén O; Gustafsson B; Sadeghi B
Article: BLOOD ADVANCES. 2019;3(20):3123-3131

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Bejanyan N; Kim S; Hebert KM; Kekre N; Abdel-Azim H; Ahmed I; Aljurf M; Badawy SM; Beitinjaneh A; Boelens JJ; Diaz MA; Dvorak CC; Gadalla S; Gajewski J; Gale RP; Ganguly S; Gennery AR; George B; Gergis U; Gómez-Almaguer D; Vicent MG; Hashem H; Kamble RT; Kasow KA; Lazarus HM; Mathews V; Orchard PJ; Pulsipher M; Ringden O; Schultz K; Teira P; Woolfrey AE; Saldaña BD; Savani B; Winiarski J; Yared J; Weisdorf DJ; Antin JH; Eapen M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(10):1975-1983

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O; Boumendil A; Labopin M; Canaani J; Beelen D; Ehninger G; Niederwieser D; Finke J; Stelljes M; Gerbitz A; Ganser A; Kröger N; Kantz L; Brecht A; Savani B; Sadeghi B; Mohty M; Nagler A
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(10):1965-1969

Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease.

Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1744-1755

Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Hamilton BK; Liu Y; Hemmer MT; Majhail N; Ringden O; Kim D; Costa L; Stuart R; Alousi A; Pidala JA; Couriel DR; Aljurf M; Antin JH; Bredeson C; Cahn J-Y; Cairo M; Choi SW; Dandoy C; Gale RP; Gergis U; Hematti P; Inamoto Y; Kamble RT; MacMillan M; Marks DI; Nemecek E; Nishihori T; Saad A; Savani BN; Schriber J; Seo S; Socié G; Teshima T; Verdonck LF; Waller EK; Wirk M; Spellman SR; Arora M; Chhabra S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1875-1883

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawal V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn J-Y; Cairo M; Castillo P; Chhabra S; Diaz MA; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryan A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Patel SS; Qayed M; Rangarajan HG; Reshef R; Ringden O; Savani BN; Schouten HC; Schultz KR; Seo S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Article: BLOOD ADVANCES. 2019;3(12):1826-1836

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Rashidi A; Hamadani M; Zhang M-J; Wang H-L; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn J-Y; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz M-A; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee J-W; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Article: CLINICAL TRANSPLANTATION. 2019;33(6):e13537

The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.

Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Article: TRANSPLANTATION. 2019;103(6):1247-1252

The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor.

Ringden O; Remberger M; Gustafsson B; Moretti G; Mattsson J; Winiarski J; Sadeghi B
Article: BLOOD ADVANCES. 2019;3(9):1441-1449

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2019;184(5):782-787

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.

Schmid C; Labopin M; Schaap N; Veelken H; Schleuning M; Stadler M; Finke J; Hurst E; Baron F; Ringden O; Bug G; Blaise D; Tischer J; Bloor A; Esteve J; Giebel S; Savani B; Gorin N-C; Ciceri F; Mohty M; Nagler A; EBMT Acute Leukaemia Working Party
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(2):270-278

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn J-Y; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(2):362-368

Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Norkin M; Shaw BE; Brazauskas R; Tecca HR; Leather HL; Gea-Banacloche J; T Kamble R; DeFilipp Z; Jacobsohn DA; Ringden O; Inamoto Y; A Kasow K; Buchbinder D; Shaw P; Hematti P; Schears R; Badawy SM; Lazarus HM; Bhatt N; Horn B; Chhabra S; M Page K; Hamilton B; Hildebrandt GC; Yared JA; Agrawal V; M Beitinjaneh A; Majhail N; Kindwall-Keller T; Olsson RF; Schoemans H; Gale RP; Ganguly S; A Ahmed I; Schouten HC; L Liesveld J; Khera N; Steinberg A; Shah AJ; Solh M; Marks DI; Rybka W; Aljurf M; Dietz AC; Gergis U; George B; Seo S; Flowers MED; Battiwalla M; Savani BN; Riches ML; Wingard JR
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2685

Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells.

Sadeghi B; Moretti G; Arnberg F; Samén E; Kohein B; Catar R; Kamhieh-Milz J; Geissler S; Moll G; Holmin S; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(1):73-85

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn J-Y; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Article: BLOOD ADVANCES. 2018;2(21):2922-2936

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S; Ahn KW; Hu Z-H; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Article: EUROPEAN JOURNAL OF CANCER. 2018;96:73-81

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S; Labopin M; Potter M; Poiré X; Sengeloev H; Socié G; Huynh A; Afanasyev BV; Schanz U; Ringden O; Kalhs P; Beelen DW; Campos AM; Masszi T; Canaani J; Mohty M; Nagler A
Article: BLOOD ADVANCES. 2018;2(9):1022-1031

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Kumar AJ; Kim S; Hemmer MT; Arora M; Spellman SR; Pidala JA; Couriel DR; Alousi AM; Aljurf MD; Cahn J-Y; Cairo MS; Cutler CS; Farhan S; Gergis U; Hale GA; Hashmi SK; Inamoto Y; Kamble RT; Kharfan-Dabaja MA; MacMillan ML; Marks DI; Nakasone H; Norkin M; Qayed M; Ringden O; Schouten HC; Schultz KR; Solh MM; Teshima T; Urbano-Ispizua A; Verdonck LF; Gale RP; Hamilton BK; Majhail NS; Loren AW
Article: MEDICAL ONCOLOGY. 2018;35(6):79

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Afram G; Simón JAP; Remberger M; Caballero-Velázquez T; Martino R; Piñana JL; Ringden O; Esquirol A; Lopez-Corral L; Garcia I; López-Godino O; Sierra J; Caballero D; Ljungman P; Vazquez L; Hägglund H
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2018;107(4):478-485

Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.

Ringdén O; Sadeghi B; Moretti G; Finnbogadottir S; Eriksson B; Mattsson J; Svahn B-M; Remberger M
Article: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2018;33(4):574-585

Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression.

Zickler D; Luecht C; Willy K; Chen L; Witowski J; Girndt M; Fiedler R; Storr M; Kamhieh-Milz J; Schoon J; Geissler S; Ringdén O; Schindler R; Moll G; Dragun D; Catar R
Article: STEM CELLS TRANSLATIONAL MEDICINE. 2018;7(4):325-331

Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.

Ringden O; Baygan A; Remberger M; Gustafsson B; Winiarski J; Khoein B; Moll G; Klingspor L; Westgren M; Sadeghi B
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2018;24(3):521-528

Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.

Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
Article: BONE MARROW TRANSPLANTATION. 2018;53(2):213-218

Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.

Crocchiolo R; Ringden O; Bay J-O; Blaise D; Omasic B; Mazzi B; Picard C; Trinca S; Barkholt L; Peccatori J; Gregori S; Amodio G; Fleischhauer K; Ciceri F; Bregni M
Article: JOURNAL OF INTERNAL MEDICINE. 2018;283(2):166-177

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Ringdén O; Labopin M; Sadeghi B; Mailhol A; Beelen D; Fløisand Y; Ghavamzadeh A; Finke J; Ehninger G; Volin L; Socié G; Kröger N; Stuhler G; Ganser A; Schmid C; Giebel S; Mohty M; Nagler A
Article: ACTA HAEMATOLOGICA. 2018;139(2):106-114

Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation.

Aronsson-Kurttila W; Baygan A; Moretti G; Remberger M; Khoein B; Moll G; Sadeghi B; Ringdén O
Article: FRONTIERS IN IMMUNOLOGY. 2018;9:760

Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation.

Poiret T; Axelsson-Robertson R; Remberger M; Luo X-H; Rao M; Nagchowdhury A; Von Landenberg A; Ernberg I; Ringden O; Maeurer M
Article: PEDIATRIC TRANSPLANTATION. 2017;21(5)

Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease.

Gustafsson B; Frisk P; Szakos A; Sadeghi B; Ringdén O; Frost B-M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2017;23(8):1327-1334

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.

Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
Article: JOURNAL OF IMMUNOTHERAPY. 2017;40(4):132-139

A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer.

Omazic B; Ayoglu B; Löhr M; Segersvärd R; Verbeke C; Magalhaes I; Potacova Z; Mattsson J; Terman A; Ghazi S; Albiin N; Kartalis N; Nilsson P; Poiret T; Zhenjiang L; Heuchel R; Schwenk JM; Permert J; Maeurer MJ; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2017;52(3):400-408

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen Y-B; Wang T; Hemmer MT; Brady C; Couriel DR; Alousi A; Pidala J; Urbano-Ispizua A; Choi SW; Nishihori T; Teshima T; Inamoto Y; Wirk B; Marks DI; Abdel-Azim H; Lehmann L; Yu L; Bitan M; Cairo MS; Qayed M; Salit R; Gale RP; Martino R; Jaglowski S; Bajel A; Savani B; Frangoul H; Lewis ID; Storek J; Askar M; Kharfan-Dabaja MA; Aljurf M; Ringden O; Reshef R; Olsson RF; Hashmi S; Seo S; Spitzer TR; MacMillan ML; Lazaryan A; Spellman SR; Arora M; Cutler CS
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2017;101(3):623-632

Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells.

Erkers T; Solders M; Verleng L; Bergström C; Stikvoort A; Rane L; Nava S; Ringdén O; Kaipe H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2017;176(3):431-439

Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.

Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M; Acute Leukaemia Working Party of the EBMT
Article: FRONTIERS IN IMMUNOLOGY. 2017;8:795

Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis.

Baygan A; Aronsson-Kurttila W; Moretti G; Tibert B; Dahllöf G; Klingspor L; Gustafsson B; Khoein B; Moll G; Hausmann C; Svahn B-M; Westgren M; Remberger M; Sadeghi B; Ringden O
Article: DERMATOLOGY. 2017;233(4):303-313

Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin.

Feldreich N; Ringden O; Emtestam L
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2017;92(1):42-49

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Rosko A; Wang H-L; de Lima M; Sandmaier B; Khoury HJ; Artz A; Brammer J; Bredeson C; Farag S; Kharfan-Dabaja M; Lazarus HM; Marks DI; Bufarull RM; McGuirk J; Mohty M; Nishihori T; Nivison-Smith I; Rashidi A; Ringden O; Seftel M; Weisdorf D; Bachanova V; Saber W
Article: HAEMATOLOGICA. 2016;101(11):1426-1433

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Artz AS; Logan B; Zhu X; Akpek G; Bufarull RM; Gupta V; Lazarus HM; Litzow M; Loren A; Majhail NS; Maziarz RT; McCarthy P; Popat U; Saber W; Spellman S; Ringden O; Wickrema A; Pasquini MC; Cooke KR; from the Center for International Blood and Marrow
Article: HAEMATOLOGICA. 2016;101(11):1417-1425

A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
Article: PEDIATRIC TRANSPLANTATION. 2016;20(5):667-674

Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades.

Svenberg P; Remberger M; Uzunel M; Mattsson J; Gustafsson B; Fjaertoft G; Sundin M; Winiarski J; Ringdén O
Article: TRANSPLANTATION. 2016;100(6):1356-1362

Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency: The Karolinska Experience.

Olsson RF; Hagelberg S; Schiller B; Ringdén O; Truedsson L; Åhlin A
Article: ONCOTARGET. 2016;7(21):30230-30240

Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.

Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(4):676-681

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer.

Omazic B; Remberger M; Barkholt L; Söderdahl G; Potácová Z; Wersäll P; Ericzon B-G; Mattsson J; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(2):248-257

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

Pasquini MC; Zhang M-J; Medeiros BC; Armand P; Hu Z-H; Nishihori T; Aljurf MD; Akpek G; Cahn J-Y; Cairo MS; Cerny J; Copelan EA; Deol A; Freytes CO; Gale RP; Ganguly S; George B; Gupta V; Hale GA; Kamble RT; Klumpp TR; Lazarus HM; Luger SM; Liesveld JL; Litzow MR; Marks DI; Martino R; Norkin M; Olsson RF; Oran B; Pawarode A; Pulsipher MA; Ramanathan M; Reshef R; Saad AA; Saber W; Savani BN; Schouten HC; Ringdén O; Tallman MS; Uy GL; Wood WA; Wirk B; Pérez WS; Batiwalla M; Weisdorf DJ
Article: LEUKEMIA. 2016;30(2):447-455

Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?

Ringdén O; Labopin M; Ciceri F; Velardi A; Bacigalupo A; Arcese W; Ghavamzadeh A; Hamladji RM; Schmid C; Nagler A; Mohty M
Article: DERMATOLOGY. 2016;232(4):453-463

Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease.

Feldreich N; Ringden O; Emtestam L; Omazic B
Article: CELL TRANSPLANTATION. 2016;25(2):401-410

Intra-arterial Administration of Placenta-Derived Decidual Stromal Cells to the Superior Mesenteric Artery in the Rabbit: Distribution of Cells, Feasibility, and Safety.

Arnberg F; Lundberg J; Olsson A; Samén E; Jaff N; Jussing E; Dahlén U; Nava S; Axelsson R; Ringdén O; Kaipe H; Holmin S
Article: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2016;951:77-98

Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?

Moll G; Geißler S; Catar R; Ignatowicz L; Hoogduijn MJ; Strunk D; Bieback K; Ringdén O
Article: CYTOTHERAPY. 2015;17(12):1732-1745

Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo.

Sadeghi B; Heshmati Y; Khoein B; Kaipe H; Uzunel M; Walfridsson J; Ringdén O
Article: TRANSFUSION. 2015;55(10):2339-2350

Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation.

Watz E; Remberger M; Ringden O; Ljungman P; Sundin M; Mattsson J; Uhlin M
Article: STEM CELLS AND DEVELOPMENT. 2015;24(19):2269-2279

Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua.

Moll G; Ignatowicz L; Catar R; Luecht C; Sadeghi B; Hamad O; Jungebluth P; Dragun D; Schmidtchen A; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(9):1589-1596

Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg K-J; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
Article: STEM CELLS AND DEVELOPMENT. 2015;24(12):1471-1482

Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Kaipe H; Carlson L-M; Erkers T; Nava S; Molldén P; Gustafsson B; Qian H; Li X; Hashimoto T; Sadeghi B; Alheim M; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(5):711-718

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning.

Veys PA; Nanduri V; Baker KS; He W; Bandini G; Biondi A; Dalissier A; Davis JH; Eames GM; Egeler RM; Filipovich AH; Fischer A; Jürgens H; Krance R; Lanino E; Leung WH; Matthes S; Michel G; Orchard PJ; Pieczonka A; Ringdén O; Schlegel PG; Sirvent A; Vettenranta K; Eapen M
Article: SUPPORTIVE CARE IN CANCER. 2015;23(6):1749-1757

The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients.

Legert KG; Tsilingaridis G; Remberger M; Ringdèn O; Heimdahl A; Yucel-Lindberg T; Dahllöf G
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(5):889-893

Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.

Remberger M; Törlén J; Ringdén O; Engström M; Watz E; Uhlin M; Mattsson J
Article: STEM CELLS AND DEVELOPMENT. 2015;24(2):253-263

Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling.

Erkers T; Kaipe H; Nava S; Molldén P; Gustafsson B; Axelsson R; Ringdén O
Article: BLOOD. 2014;124(26):3996-4003

HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.

Petersdorf EW; Gooley TA; Malkki M; Bacigalupo AP; Cesbron A; Du Toit E; Ehninger G; Egeland T; Fischer GF; Gervais T; Haagenson MD; Horowitz MM; Hsu K; Jindra P; Madrigal A; Oudshoorn M; Ringdén O; Schroeder ML; Spellman SR; Tiercy J-M; Velardi A; Witt CS; O'Huigin C; Apps R; Carrington M; International Histocompatibility Working Group in
Article: BONE MARROW TRANSPLANTATION. 2014;49(12):1486-1491

Superselective intra-arterial umbilical cord blood administration to BM in experimental animals.

Arnberg F; Lundberg J; Kenne E; Jaff N; Müller P; Nava S; Kaipe H; Ringdén O; Holmin S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(11):1777-1784

Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.

Ringdén O; Brazauskas R; Wang Z; Ahmed I; Atsuta Y; Buchbinder D; Burns LJ; Cahn J-Y; Duncan C; Hale GA; Halter J; Hayashi RJ; Hsu JW; Jacobsohn DA; Kamble RT; Kamani NR; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Myers KC; Ramanathan M; Saber W; Savani BN; Schouten HC; Socie G; Sorror ML; Steinberg A; Popat U; Wingard JR; Mattsson J; Majhail NS
Article: JOURNAL OF IMMUNOTHERAPY. 2014;37(8):416-425

TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation.

Ahmed RK; Poiret T; Ambati A; Rane L; Remberger M; Omazic B; Vudattu NK; Winiarski J; Ernberg I; Axelsson-Robertson R; Magalhaes I; Castelli C; Ringden O; Maeurer M
Article: TRANSPLANTATION. 2014;98(5):569-577

Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?

Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji R-M; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M; Acute Leukaemia Working Party of the European Grou
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(9):1418-1425

Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Törlén J; Ringdén O; Le Rademacher J; Batiwalla M; Chen J; Erkers T; Ho V; Kebriaei P; Keever-Taylor C; Kindwall-Keller T; Lazarus HM; Laughlin MJ; Lill M; O'Brien T; Perales M-A; Rocha V; Savani BN; Szwajcer D; Valcarcel D; Eapen M
Article: SUPPORTIVE CARE IN CANCER. 2014;22(8):2133-2140

Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.

Legert KG; Remberger M; Ringdén O; Heimdahl A; Dahllöf G
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(8):4941-4943

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

Blennow O; Eliasson E; Pettersson T; Pohanka A; Szakos A; El-Serafi I; Hassan M; Ringdén O; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2014;49(8):1046-1051

Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy.

Solders M; Martin DA; Andersson C; Remberger M; Andersson T; Ringdén O; Solders G
Article: BMC IMMUNOLOGY. 2014;15:25

Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults.

Poiret T; Rane L; Remberger M; Omazic B; Gustafsson-Jernberg A; Vudattu NK; Ahmed R; Ernberg I; Winiarski J; Magalhaes I; Ringden O; Maeurer M
Article: PEDIATRIC TRANSPLANTATION. 2014;18(4):398-404

Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital.

Ringdén O; Remberger M; Törlén J; Engström M; Fjaertoft G; Mattsson J; Svahn B-M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(2):264-271

Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.

Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(2):202-208

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.

Warlick ED; Paulson K; Brazauskas R; Zhong X; Miller AM; Camitta BM; George B; Savani BN; Ustun C; Marks DI; Waller EK; Baron F; Freytes CO; Socie G; Akpek G; Schouten HC; Lazarus HM; Horwitz EM; Koreth J; Cahn J-Y; Bornhauser M; Seftel M; Cairo MS; Laughlin MJ; Sabloff M; Ringdén O; Gale RP; Kamble RT; Vij R; Gergis U; Mathews V; Saber W; Chen Y-B; Liesveld JL; Cutler CS; Ghobadi A; Uy GL; Eapen M; Weisdorf DJ; Litzow MR
Article: BONE MARROW TRANSPLANTATION. 2014;49(2):168-173

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

Ruutu T; Gratwohl A; de Witte T; Afanasyev B; Apperley J; Bacigalupo A; Dazzi F; Dreger P; Duarte R; Finke J; Garderet L; Greinix H; Holler E; Kröger N; Lawitschka A; Mohty M; Nagler A; Passweg J; Ringdén O; Socié G; Sierra J; Sureda A; Wiktor-Jedrzejczak W; Madrigal A; Niederwieser D
Article: HAEMATOLOGICA. 2014;99(2):346-352

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.

Uhlin M; Wikell H; Sundin M; Blennow O; Maeurer M; Ringden O; Winiarski J; Ljungman P; Remberger M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(1):135-138

Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.

Ruutu T; Juvonen E; Remberger M; Remes K; Volin L; Mattsson J; Nihtinen A; Hägglund H; Ringdén O; Nordic Group for Blood and Marrow Transplantation
Article: BLOOD. 2013;122(22):3651-3658

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Pidala J; Wang T; Haagenson M; Spellman SR; Askar M; Battiwalla M; Baxter-Lowe LA; Bitan M; Fernandez-Viña M; Gandhi M; Jakubowski AA; Maiers M; Marino SR; Marsh SGE; Oudshoorn M; Palmer J; Prasad VK; Reddy V; Ringden O; Saber W; Santarone S; Schultz KR; Setterholm M; Trachtenberg E; Turner EV; Woolfrey AE; Lee SJ; Anasetti C
Article: ACTA PAEDIATRICA. 2013;102(11):1087-1094

Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment.

Åhlin A; Fugeläng J; de Boer M; Ringden O; Fasth A; Winiarski J
Article: STEM CELLS AND DEVELOPMENT. 2013;22(19):2596-2605

Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner.

Erkers T; Nava S; Yosef J; Ringdén O; Kaipe H
Article: STEM CELLS. 2013;31(8):1715-1725

Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.

Jitschin R; Mougiakakos D; Von Bahr L; Völkl S; Moll G; Ringden O; Kiessling R; Linder S; Le Blanc K
Article: JOURNAL OF INTERNAL MEDICINE. 2013;274(2):153-162

A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.

Ringdén O; Erkers T; Aschan J; Garming-Legert K; Le Blanc K; Hägglund H; Omazic B; Svenberg P; Dahllöf G; Mattsson J; Ljungman P; Remberger M
Article: CLINICAL TRANSPLANTATION. 2013;27(4):E368-E374

A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.

Remberger M; Ringdén O; Hägglund H; Svahn B-M; Ljungman P; Uhlin M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):825-831

Effects of spleen status on early outcomes after hematopoietic cell transplantation.

Akpek G; Pasquini MC; Logan B; Agovi M-A; Lazarus HM; Marks DI; Bornhaeüser M; Ringdén O; Maziarz RT; Gupta V; Popat U; Maharaj D; Bolwell BJ; Rizzo JD; Ballen KK; Cooke KR; McCarthy PL; Ho VT
Article: PEDIATRIC TRANSPLANTATION. 2013;17(3):285-293

Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning.

Mårtensson T; Priftakis P; Casswall T; Ringdén O; Mattsson J; Remberger M; Hassan M; Gustafsson B
Article: BONE MARROW TRANSPLANTATION. 2013;48(4):537-543

Graft failure in the modern era of allogeneic hematopoietic SCT.

Olsson R; Remberger M; Schaffer M; Berggren DM; Svahn B-M; Mattsson J; Ringden O
Article: STEM CELLS. 2013;31(3):592-601

Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease.

Ringdén O; Erkers T; Nava S; Uzunel M; Iwarsson E; Conrad R; Westgren M; Mattsson J; Kaipe H
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2013;19(2):314-320

Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease.

Ringdén O; Remberger M; Holmberg K; Edeskog C; Wikström M; Eriksson B; Finnbogadottir S; Fransson K; Milovsavljevic R; Omazic B; Svenberg P; Mattsson J; Svahn B-M
Article: MEDICAL ONCOLOGY. 2012;29(4):2348-2358

Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.

Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hägglund H
Article: TRANSPLANTATION. 2012;94(10):1066-1074

Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation.

Berglund S; Le Blanc K; Remberger M; Gertow J; Uzunel M; Svenberg P; Winiarski J; Ljungman P; Ringdén O; Uhlin M; Mattsson J
Article: JOURNAL OF INTERNAL MEDICINE. 2012;272(5):472-483

Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients.

Ringdén O; Labopin M; Beelen DW; Volin L; Ehninger G; Finke J; Greinix HT; Kyrcz-Krzemien S; Bunjes D; Brinch L; Niederwieser D; Arnold R; Mohty M; Rocha V; Acute Leukaemia Working Party of European Group fo
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(9):1438-1445

Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.

Eapen M; Ahn KW; Orchard PJ; Cowan MJ; Davies SM; Fasth A; Hassebroek A; Ayas M; Bonfim C; O'Brien TA; Gross TG; Horwitz M; Horwitz E; Kapoor N; Kurtzberg J; Majhail N; Ringden O; Szabolcs P; Veys P; Baker KS
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2012;89(3):220-227

Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation.

Forslöw U; Blennow O; LeBlanc K; Ringdén O; Gustafsson B; Mattsson J; Remberger M
Article: HAEMATOLOGICA. 2012;97(8):1187-1195

Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Pérez-Simón JA; Afram G; Martino R; Piñana JL; Caballero-Velazquez T; Ringden O; Valcarcel D; Caballero D; Remberger M; de Paz Y; Sierra J; Miguel JS; Hagglund H
Article: STEM CELLS. 2012;30(7):1575-1578

Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.

von Bahr L; Batsis I; Moll G; Hägg M; Szakos A; Sundberg B; Uzunel M; Ringden O; Le Blanc K
Article: STEM CELLS. 2012;30(7):1565-1574

Are therapeutic human mesenchymal stromal cells compatible with human blood?

Moll G; Rasmusson-Duprez I; von Bahr L; Connolly-Andersen A-M; Elgue G; Funke L; Hamad OA; Lönnies H; Magnusson PU; Sanchez J; Teramura Y; Nilsson-Ekdahl K; Ringdén O; Korsgren O; Nilsson B; Le Blanc K
Article: STEM CELLS AND DEVELOPMENT. 2012;21(9):1409-1417

Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation.

Uhlin M; Sairafi D; Berglund S; Thunberg S; Gertow J; Ringden O; Uzunel M; Remberger M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2012;47(6):831-837

Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma.

Ringdén O; Shrestha S; da Silva GT; Zhang M-J; Dispenzieri A; Remberger M; Kamble R; Freytes CO; Gale RP; Gibson J; Gupta V; Holmberg L; Lazarus H; McCarthy P; Meehan K; Schouten H; Milone GA; Lonial S; Hari PN
Article: BONE MARROW TRANSPLANTATION. 2012;47(5):706-715

Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation.

Svahn B-M; Remberger M; Alvin O; Karlsson H; Ringdén O
Article: LANCET ONCOLOGY. 2012;13(4):366-374

Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.

Fleischhauer K; Shaw BE; Gooley T; Malkki M; Bardy P; Bignon J-D; Dubois V; Horowitz MM; Madrigal JA; Morishima Y; Oudshoorn M; Ringden O; Spellman S; Velardi A; Zino E; Petersdorf EW; International Histocompatibility Working Group in
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2012;157(2):220-229

Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation.

Ringdén O; Labopin M; Gorin N-C; Volin L; Torelli GF; Attal M; Jouet JP; Milpied N; Socié G; Cordonnier C; Michallet M; Atienza AI; Hermine O; Mohty M; Acute Leukaemia Working Party of the European Grou
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(4):557-564

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.

von Bahr L; Sundberg B; Lönnies L; Sander B; Karbach H; Hägglund H; Ljungman P; Gustafsson B; Karlsson H; Le Blanc K; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2012;47(3):404-410

Salivary secretion in children after fractionated or single-dose TBI.

Garming Legert K; Remberger M; Ringdèn O; Heimdahl A; Dahllöf G
Article: ORTHODONTICS & CRANIOFACIAL RESEARCH. 2012;15(1):21-29

Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation.

Vesterbacka M; Ringdén O; Remberger M; Huggare J; Dahllöf G
Article: BONE MARROW TRANSPLANTATION. 2012;47(2):203-211

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Luger SM; Ringdén O; Zhang M-J; Pérez WS; Bishop MR; Bornhauser M; Bredeson CN; Cairo MS; Copelan EA; Gale RP; Giralt SA; Gulbas Z; Gupta V; Hale GA; Lazarus HM; Lewis VA; Lill MC; McCarthy PL; Weisdorf DJ; Pulsipher MA
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2012;167(3):543-555

Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

Karlsson H; Erkers T; Nava S; Ruhm S; Westgren M; Ringdén O
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;87(6):503-509

Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.

Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(12):1796-1803

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Farag SS; Maharry K; Zhang M-J; Pérez WS; George SL; Mrózek K; DiPersio J; Bunjes DW; Marcucci G; Baer MR; Cairo M; Copelan E; Cutler CS; Isola L; Lazarus HM; Litzow MR; Marks DI; Ringdén O; Rizzieri DA; Soiffer R; Larson RA; Tallman MS; Bloomfield CD; Weisdorf DJ; Acute Leukemia Committee of the Center for Interna
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(11):1688-1697

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.

Remberger M; Ackefors M; Berglund S; Blennow O; Dahllöf G; Dlugosz A; Garming-Legert K; Gertow J; Gustafsson B; Hassan M; Hassan Z; Hauzenberger D; Hägglund H; Karlsson H; Klingspor L; Kumlien G; Le Blanc K; Ljungman P; Machaczka M; Malmberg K-J; Marschall H-U; Mattsson J; Olsson R; Omazic B; Sairafi D; Schaffer M; Svahn B-M; Svenberg P; Swartling L; Szakos A; Uhlin M; Uzunel M; Watz E; Wernerson A; Wikman A; Wikström A-C; Winiarski J; Ringdén O
Article: ORAL DISEASES. 2011;17(7):670-676

Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.

Garming-Legert K; Remberger M; Ringdén O; Hassan M; Dahllöf G
Article: ORAL ONCOLOGY. 2011;47(9):915-919

Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan.

Dahllöf G; Wondimu B; Barr-Agholme M; Garming-Legert K; Remberger M; Ringdén O
Article: TRANSPLANT IMMUNOLOGY. 2011;25(2-3):153-158

Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation.

Nordlander A; Uhlin M; Ringdén O; Kumlien G; Hauzenberger D; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(6):885-892

HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

Woolfrey A; Klein JP; Haagenson M; Spellman S; Petersdorf E; Oudshoorn M; Gajewski J; Hale GA; Horan J; Battiwalla M; Marino SR; Setterholm M; Ringden O; Hurley C; Flomenberg N; Anasetti C; Fernandez-Vina M; Lee SJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(5):640-648

One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.

Valcárcel D; Sierra J; Wang T; Kan F; Gupta V; Hale GA; Marks DI; McCarthy PL; Oudshoorn M; Petersdorf EW; Ringdén O; Setterholm M; Spellman SR; Waller EK; Gajewski JL; Marino SR; Senitzer D; Lee SJ
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2011;41(4):1143-1153

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro.

Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringdén O
Article: BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2011;24(1):65-72

Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages.

Ringden O; Le Blanc K
Article: PEDIATRIC BLOOD & CANCER. 2011;56(3):444-451

Hematopoietic stem cell transplantation in severe congenital neutropenia.

Carlsson G; Winiarski J; Ljungman P; Ringdén O; Mattsson J; Nordenskjöld M; Touw I; Henter J-I; Palmblad J; Fadeel B; Hägglund H
Article: BONE MARROW TRANSPLANTATION. 2011;46(2):200-207

Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation.

Bernardo ME; Ball LM; Cometa AM; Roelofs H; Zecca M; Avanzini MA; Bertaina A; Vinti L; Lankester A; Maccario R; Ringden O; Le Blanc K; Egeler RM; Fibbe WE; Locatelli F
Article: BONE MARROW TRANSPLANTATION. 2011;46(1):34-43

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.

Uberti JP; Agovi M-A; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
Article: PLOS ONE. 2011;6(7):e21703

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses.

Moll G; Jitschin R; von Bahr L; Rasmusson-Duprez I; Sundberg B; Lönnies L; Elgue G; Nilsson-Ekdahl K; Mougiakakos D; Lambris JD; Ringdén O; Le Blanc K; Nilsson B
Article: CLINICAL TRANSPLANTATION. 2011;25(1):E68-E76

Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure.

Remberger M; Mattsson J; Olsson R; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2010;45(12):1710-1718

Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

Blennow O; Remberger M; Klingspor L; Omazic B; Fransson K; Ljungman P; Mattsson J; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2010;16(12):1728-1737

Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.

Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
Article: HAEMATOLOGICA. 2010;95(12):2119-2125

Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors.

Gupta V; Eapen M; Brazauskas R; Carreras J; Aljurf M; Gale RP; Hale GA; Ilhan O; Passweg JR; Ringdén O; Sabloff M; Schrezenmeier H; Socié G; Marsh JCW
Article: TRANSPLANTATION. 2010;90(9):1022-1029

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.

Ringden O; Hassan Z; Karlsson H; Olsson R; Omazic B; Mattsson J; Remberger M
Article: BLOOD. 2010;116(19):4007-4015

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.

Shaw PJ; Kan F; Woo Ahn K; Spellman SR; Aljurf M; Ayas M; Burke M; Cairo MS; Chen AR; Davies SM; Frangoul H; Gajewski J; Gale RP; Godder K; Hale GA; Heemskerk MBA; Horan J; Kamani N; Kasow KA; Chan KW; Lee SJ; Leung WH; Lewis VA; Miklos D; Oudshoorn M; Petersdorf EW; Ringdén O; Sanders J; Schultz KR; Seber A; Setterholm M; Wall DA; Yu L; Pulsipher MA
Article: TRANSPLANTATION. 2010;90(2):124-126

Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).

Hoogduijn MJ; Popp FC; Grohnert A; Crop MJ; van Rhijn M; Rowshani AT; Eggenhofer E; Renner P; Reinders ME; Rabelink TJ; van der Laan LJW; Dor FJMF; Ijzermans JNM; Genever PG; Lange C; Durrbach A; Houtgraaf JH; Christ B; Seifert M; Shagidulin M; Donckier V; Deans R; Ringden O; Perico N; Remuzzi G; Bartholomew A; Schlitt HJ; Weimar W; Baan CC; Dahlke MH; MISOT Study Group
Article: BLOOD. 2010;115(13):2686-2694

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.

Björklund AT; Schaffer M; Fauriat C; Ringdén O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren H-G; Malmberg K-J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2010;84(4):323-331

GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.

Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2010;45(4):682-688

Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit.

Gilli K; Remberger M; Hjelmqvist H; Ringden O; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2010;45(2):235-238

Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection.

Mattsson J; Nordlander A; Remberger M; Uhlin M; Holgersson J; Ringdén O; Hauzenberger D
Article: JOURNAL OF IMMUNOTHERAPY. 2010;33(1):96-105

Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation.

Okas M; Gertow J; Uzunel M; Karlsson H; Westgren M; Kärre K; Ringden O; Mattsson J; Uhlin M
Article: BONE MARROW TRANSPLANTATION. 2009;44(11):757-763

Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism.

Svenberg P; Mattsson J; Ringdén O; Uzunel M
Article: VOX SANGUINIS. 2009;97(3):254-259

A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.

Diedrich B; Ringdén O; Watz E; Shanwell A
Article: TRANSPLANT INFECTIOUS DISEASE. 2009;11(5):393-399

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.

Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(10):1277-1287

The effect of smoking on allogeneic transplant outcomes.

Marks DI; Ballen K; Logan BR; Wang Z; Sobocinski KA; Bacigalupo A; Burns LJ; Gupta V; Ho V; McCarthy PL; Ringdén O; Schouten HC; Seftel M; Rizzo JD
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(27):4570-4577

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin N-C; Mohty M; Rocha V
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(9):1108-1115

Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.

Le Blanc K; Barrett AJ; Schaffer M; Hägglund H; Ljungman P; Ringdén O; Remberger M
Article: JOURNAL OF IMMUNOTHERAPY. 2009;32(7):755-764

HSCT recipients have specific tolerance to MSC but not to the MSC donor.

Sundin M; Barrett AJ; Ringdén O; Uzunel M; Lönnies H; Dackland A-L; Christensson B; Blanc KL
Article: IMMUNOTHERAPY. 2009;1(5):753-764

Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren H-G; Dilber MS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;145(6):816-824

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.

Ratanatharathorn V; Logan B; Wang D; Horowitz M; Uberti JP; Ringden O; Gale RP; Khoury H; Arora M; Spellman S; Cutler C; Antin J; Bornhaüser M; Hale G; Verdonck L; Cairo M; Gupta V; Pavletic S; Center for International Blood and Marrow Transpla
Article: BONE MARROW TRANSPLANTATION. 2009;43(7):553-561

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.

Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
Article: BLOOD. 2009;113(13):3110-3118

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Ringdén O; Pavletic SZ; Anasetti C; Barrett AJ; Wang T; Wang D; Antin JH; Di Bartolomeo P; Bolwell BJ; Bredeson C; Cairo MS; Gale RP; Gupta V; Hahn T; Hale GA; Halter J; Jagasia M; Litzow MR; Locatelli F; Marks DI; McCarthy PL; Cowan MJ; Petersdorf EW; Russell JA; Schiller GJ; Schouten H; Spellman S; Verdonck LF; Wingard JR; Horowitz MM; Arora M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(3):360-366

Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants.

Davies SM; Wang D; Wang T; Arora M; Ringden O; Anasetti C; Pavletic S; Casper J; Macmillan ML; Sanders J; Wall D; Kernan NA
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(3):326-335

Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience.

Aglietta M; Barkholt L; Schianca FC; Caravelli D; Omazic B; Minotto C; Leone F; Hentschke P; Bertoldero G; Capaldi A; Ciccone G; Niederwieser D; Ringdén O; Demirer T; EBMT Solid Tumor Working Party
Article: TRANSPLANTATION. 2009;87(4):467-472

Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.

Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
Article: CYTOTHERAPY. 2009;11(2):129-136

Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells.

Samuelsson H; Ringdén O; Lönnies H; Le Blanc K
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(35):5728-5734

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Hahn T; McCarthy PL; Zhang M-J; Wang D; Arora M; Frangoul H; Gale RP; Hale GA; Horan J; Isola L; Maziarz RT; van Rood JJ; Gupta V; Halter J; Reddy V; Tiberghien P; Litzow M; Anasetti C; Pavletic S; Ringdén O
Article: HLA. 2008;72(6):549-558

Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.

Hauzenberger D; Schaffer M; Ringdén O; Hassan Z; Omazic B; Mattsson J; Wikström A-C; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;42(10):643-648

Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor.

Ringdén O; Okas M; Uhlin M; Uzunel M; Remberger M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2008;42(3):201-205

Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.

Levine JE; Barrett AJ; Zhang M-J; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
Article: BONE MARROW TRANSPLANTATION. 2008;42(3):175-180

Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Baker KS; Filipovich AH; Gross TG; Grossman WJ; Hale GA; Hayashi RJ; Kamani NR; Kurian S; Kapoor N; Ringdén O; Eapen M
Article: ACTA PAEDIATRICA. 2008;97(8):1108-1112

Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT).

Malm G; Gustafsson B; Berglund G; Lindström M; Naess K; Borgström B; von Döbeln U; Ringdén O
Article: BLOOD. 2008;112(3):532-541

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses.

Karlsson H; Samarasinghe S; Ball LM; Sundberg B; Lankester AC; Dazzi F; Uzunel M; Rao K; Veys P; Le Blanc K; Ringdén O; Amrolia PJ
Article: BONE MARROW TRANSPLANTATION. 2008;41(11):961-964

No impact of NOD2/CARD15 on outcome after SCT.

Sairafi D; Uzunel M; Remberger M; Ringdén O; Mattsson J
Article: LANCET. 2008;371(9624):1579-1586

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Le Blanc K; Frassoni F; Ball L; Locatelli F; Roelofs H; Lewis I; Lanino E; Sundberg B; Bernardo ME; Remberger M; Dini G; Egeler RM; Bacigalupo A; Fibbe W; Ringdén O; Developmental Committee of the European Group for
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2008;80(5):419-428

Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia.

Remberger M; Mattsson J; Hausenberger D; Schaffer M; Svahn B-M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2008;41(9):785-790

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.

Barkholt L; Remberger M; Hassan Z; Fransson K; Omazic B; Svahn B-M; Karlsson H; Brune M; Hassan M; Mattsson J; Ringdén O
Article: APMIS. 2008;116(5):345-351

A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation.

Edvinsson B; Lundquist J; Ljungman P; Ringdén O; Evengård B
Article: TRANSPLANTATION. 2008;85(7):1000-1007

Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition.

Svahn B-M; Remberger M; Heijbel M; Martell E; Wikström M; Eriksson B; Milovsavljevic R; Mattsson J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2008;41(8):737-742

BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts.

Giraud G; Priftakis P; Bogdanovic G; Remberger M; Dubrulle M; Hau A; Gutmark R; Mattson J; Svahn B-M; Ringden O; Winiarski J; Ljungman P; Dalianis T
Article: BONE MARROW TRANSPLANTATION. 2008;41(7):621-625

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.

Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
Article: HAEMATOLOGICA. 2008;93(2):265-272

A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.

Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Article: BONE MARROW TRANSPLANTATION. 2008;41(3):267-273

Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival.

Norlin A-C; Sairafi D; Mattsson J; Ljungman P; Ringdén O; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;41(4):399-405

Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.

Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(1 Suppl 1):165-170

Graft failure after allogeneic hematopoietic cell transplantation.

Mattsson J; Ringdén O; Storb R
Article: CYTOTHERAPY. 2008;10(3):238-242

No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells.

Sundin M; Remberger M; Lönnies H; Sundberg B; Ringdén O; Le Blanc K
Article: BLOOD. 2007;110(13):4560-4566

The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation.

Shaw BE; Gooley TA; Malkki M; Madrigal JA; Begovich AB; Horowitz MM; Gratwohl A; Ringdén O; Marsh SGE; Petersdorf EW
Article: BONE MARROW TRANSPLANTATION. 2007;40(11):1055-1062

Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation.

Bjorklund A; Aschan J; Labopin M; Remberger M; Ringden O; Winiarski J; Ljungman P
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2007;27(6):589-597

Enhanced in vivo protein synthesis in circulating immune cells of ICU patients.

Januszkiewicz A; Klaude M; Loré K; Andersson J; Ringdén O; Rooyackers O; Wernerman J
Article: LEUKEMIA. 2007;21(11):2271-2276

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon.

Ringdén O; Uzunel M; Sundberg B; Lönnies L; Nava S; Gustafsson J; Henningsohn L; Le Blanc K
Article: BONE MARROW TRANSPLANTATION. 2007;40(9):865-869

Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT.

Avetisyan G; Aschan J; Hägglund H; Ringdén O; Ljungman P
Article: TRANSPLANTATION. 2007;84(8):1055-1059

Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum.

Le Blanc K; Samuelsson H; Lönnies L; Sundin M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2007;40(7):683-689

Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Article: HAEMATOLOGICA. 2007;92(9):1208-1215

No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients.

Sundin M; Ringdén O; Sundberg B; Nava S; Götherström C; Le Blanc K
Article: CLINICAL TRANSPLANTATION. 2007;21(5):659-667

Hemorrhagic cystitis: a retrospective single-center survey.

Hassan Z; Remberger M; Svenberg P; Elbander M; Omazic B; Mattsson J; Conrad R; Svahn B-M; Ahlgren A; Sairafi D; Aschan J; Le Blanc K; Barkholt L; Ringdén O
Article: TRANSPLANTATION. 2007;84(4):551-554

Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.

Remberger M; Ringdén O
Article: LEUKEMIA. 2007;21(8):1733-1738

Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.

Le Blanc K; Samuelsson H; Gustafsson B; Remberger M; Sundberg B; Arvidson J; Ljungman P; Lönnies H; Nava S; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(6):675-682

Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation.

Remberger M; Watz E; Ringdén O; Mattsson J; Shanwell A; Wikman A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2007;65(4):336-343

Mesenchymal stem cells stimulate antibody secretion in human B cells.

Rasmusson I; Le Blanc K; Sundberg B; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2007;39(7):383-388

Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.

Ringdén O; Remberger M; Svenberg P; Svahn B-M; Dahllöf G; Gustafsson B; Hassan Z; Omazic B; Uzunel M; Aschan J; Barkholt L; Winiarski J; Ljungman P; Mattsson J
Article: INTERNATIONAL JOURNAL OF PAEDIATRIC DENTISTRY. 2007;17(1):34-40

Longitudinal scintigraphic study of parotid and submandibular gland function after total body irradiation in children and adolescents.

Bågesund M; Richter S; Ringdén O; Dahllöf G
Article: TRANSPLANTATION. 2006;82(7):913-919

Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.

Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(8):828-836

KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.

Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon J-D; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E; International Histocompatibility Working Group
Article: HAEMATOLOGICA. 2006;91(8):1059-1067

The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Article: TRANSPLANTATION. 2006;82(2):147-153

Costs of allogeneic hematopoietic stem cell transplantation.

Svahn B-M; Alvin O; Ringdén O; Gardulf A; Remberger M
Article: ANNALS OF ONCOLOGY. 2006;17(7):1134-1140

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.

Barkholt L; Bregni M; Remberger M; Blaise D; Peccatori J; Massenkeil G; Pedrazzoli P; Zambelli A; Bay J-O; Francois S; Martino R; Bengala C; Brune M; Lenhoff S; Porcellini A; Falda M; Siena S; Demirer T; Niederwieser D; Ringdén O; French ITAC group and the EBMT Solid Tumour Workin
Article: TRANSPLANTATION. 2006;81(11):1600-1603

Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades.

Svahn B-M; Ringdén O; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2006;37(11):1051-1059

Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual.

Sundin M; Orvell C; Rasmusson I; Sundberg B; Ringdén O; Le Blanc K
Article: TRANSPLANTATION. 2006;81(10):1390-1397

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.

Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall H-U; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Article: TRANSPLANTATION. 2006;81(5):718-725

Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center.

Ringdén O; Remberger M; Svahn B-M; Barkholt L; Mattsson J; Aschan J; Le Blanc K; Gustafsson B; Hassan Z; Omazic B; Svenberg P; Solders G; von Döbeln U; Winiarski J; Ljungman P; Malm G
Article: HAEMATOLOGICA. 2006;91(3):401-404

The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen.

Giraud G; Bogdanovic G; Priftakis P; Remberger M; Svahn B-M; Barkholt L; Ringden O; Winiarski J; Ljungman P; Dalianis T
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(3):346-354

Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer.

Conrad R; Remberger M; Cederlund K; Hentschke P; Sundberg B; Ringdén O; Barkholt L
Article: BLOOD. 2006;107(4):1712-1716

Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.

Khoury HJ; Loberiza FR; Ringdén O; Barrett AJ; Bolwell BJ; Cahn J-Y; Champlin RE; Gale RP; Hale GA; Urbano-Ispizua A; Martino R; McCarthy PL; Tiberghien P; Verdonck LF; Horowitz MM
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2006;38(11-12):970-976

Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation.

Forslöw U; Mattsson J; Ringden O; Klominek J; Remberger M
Article: HAEMATOLOGICA. 2006;91(1):78-83

Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.

Ljungman P; Perez-Bercoff L; Jonsson J; Avetisyan G; Sparrelid E; Aschan J; Barkholt L; Larsson K; Winiarski J; Yun Z; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(12):1006-1013

ABO blood group barrier in allogeneic bone marrow transplantation revisited.

Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ; GVHD Working Committee of Center for International
Article: CANCER. 2005;104(10):2099-2103

Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.

Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D; European Bone Marrow Transplantation Solid Tumor W
Article: BLOOD. 2005;106(9):2969-2976

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

Crawley C; Szydlo R; Lalancette M; Bacigalupo A; Lange A; Brune M; Juliusson G; Nagler A; Gratwohl A; Passweg J; Komarnicki M; Vitek A; Mayer J; Zander A; Sierra J; Rambaldi A; Ringden O; Niederwieser D; Apperley JF; Chronic Leukemia Working Party of the EBMT
Article: BONE MARROW TRANSPLANTATION. 2005;36(6):511-516

Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.

Svahn BM; Ringdén O; Remberger M
Article: BLOOD. 2005;106(4):1495-1500

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.

Cahn J-Y; Klein JP; Lee SJ; Milpied N; Blaise D; Antin JH; Leblond V; Ifrah N; Jouet J-P; Loberiza F; Ringden O; Barrett AJ; Horowitz MM; Socié G; Société Française de Greffe de Moëlle et Thérapie ; Dana Farber Cancer Institute; International Bone Marrow Transplant Registry
Article: TRANSFUSION. 2005;45(7):1064-1072

A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.

Diedrich B; Remberger M; Shanwell A; Svahn B-M; Ringdén O
Article: TRANSPLANTATION. 2005;79(11):1607-1614

Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.

Le Blanc K; Götherström C; Ringdén O; Hassan M; McMahon R; Horwitz E; Anneren G; Axelsson O; Nunn J; Ewald U; Nordén-Lindeberg S; Jansson M; Dalton A; Aström E; Westgren M
Article: EXPERIMENTAL CELL RESEARCH. 2005;305(1):33-41

Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.

Rasmusson I; Ringdén O; Sundberg B; Le Blanc K
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2005;61(3):285-294

T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.

Hentschke P; Omazic B; Mattsson J; Näsman-Björk I; Lundkvist I; Gigliotti D; Barkholt L; Ringdén O; Remberger M
Article: BLOOD. 2005;105(4):1408-1416

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.

Oh H; Loberiza FR; Zhang M-J; Ringdén O; Akiyama H; Asai T; Miyawaki S; Okamoto S; Horowitz MM; Antin JH; Bashey A; Bird JM; Carabasi MH; Fay JW; Gale RP; Giller RH; Goldman JM; Hale GA; Harris RE; Henslee-Downey J; Kolb H-J; Litzow MR; McCarthy PL; Neudorf SM; Serna DS; Socié G; Tiberghien P; Barrett AJ
Article: CLINICAL SCIENCE. 2005;108(2):179-184

Determination of in vivo protein synthesis in human palatine tonsil.

Januszkiewicz A; Klaude M; Loré K; Andersson J; Ringdén O; Rooyackers O; Wernerman J
Article: BLOOD. 2005;105(2):548-551

Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors.

Remberger M; Beelen DW; Fauser A; Basara N; Basu O; Ringdén O
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2005;61(1):72-81

Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens.

Omazic B; Hentschke P; Näsman-Björk I; Mattsson J; Oxelius V-A; Ringdén O; Barkholt L; Permert J; Lundkvist I
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(12):877-882

Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors.

Svenberg P; Remberger M; Svennilson J; Mattsson J; Leblanc K; Gustafsson B; Aschan J; Barkholt L; Winiarski J; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2004;34(12):1067-1069

Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients.

Ljungman P; Aschan J; Gustafsson B; Lewensohn-Fuchs I; Winiarski J; Ringdén O
Article: TRANSPLANTATION. 2004;78(7):1081-1085

Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation.

Schaffer M; Malmberg K-J; Ringdén O; Ljunggren H-G; Remberger M
Article: TRANSPLANTATION. 2004;78(7):1014-1020

A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation.

Le Blanc K; Remberger M; Uzunel M; Mattsson J; Barkholt L; Ringdén O
Article: PEDIATRIC TRANSPLANTATION. 2004;8(5):464-474

Risk factors in pediatric stem cell transplantation for leukemia.

Gustafsson Jernberg A; Remberger M; Ringdén O; Winiarski J
Article: CLINICAL TRANSPLANTATION. 2004;18(5):518-524

Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients.

Liu D; Tammik C; Zou J-Z; Ernberg I; Masucci MG; Ringden O; Levitsky V
Article: BONE MARROW TRANSPLANTATION. 2004;34(8):721-727

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang M-J; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
Article: BONE MARROW TRANSPLANTATION. 2004;34(7):589-593

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease.

Ljungman P; Aschan J; Barkholt L; Broliden P-A; Gustafsson B; Lewensohn-Fuchs I; Löfgren C; Winiarski J; Ringdén O
Article: TRANSPLANTATION. 2004;78(5):697-703

Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation.

Barkholt L; Danielsson R; Calissendorff B; Svensson L; Malihi R; Remberger M; Uzunel M; Thörne A; Ringdén O
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2004;60(3):307-315

Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes.

Le Blanc K; Rasmusson I; Götherström C; Seidel C; Sundberg B; Sundin M; Rosendahl K; Tammik C; Ringdén O
Article: TRANSPLANTATION. 2004;78(3):415-419

Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors.

Malm G; Månsson J-E; Winiarski J; Mosskin M; Ringdén O
Article: TRANSPLANTATION. 2004;78(1):122-127

Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.

Remberger M; Svahn B-M; Mattsson J; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14):2816-2825

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

Kiehl MG; Kraut L; Schwerdtfeger R; Hertenstein B; Remberger M; Kroeger N; Stelljes M; Bornhaeuser M; Martin H; Scheid C; Ganser A; Zander AR; Kienast J; Ehninger G; Hoelzer D; Diehl V; Fauser AA; Ringden O
Article: LANCET. 2004;363(9419):1439-1441

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Le Blanc K; Rasmusson I; Sundberg B; Götherström C; Hassan M; Uzunel M; Ringdén O
Article: JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. 2004;127(5):1293-1300

Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium.

Grinnemo KH; Månsson A; Dellgren G; Klingberg D; Wardell E; Drvota V; Tammik C; Holgersson J; Ringdén O; Sylvén C; Le Blanc K
Article: PRESSE MEDICALE. 2004;33(7):474-478

Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trial.

Svahn B-M; Bjurman B; Myrbäck K-E; Aschan J; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(3):195-203

Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.

Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Article: TRANSPLANTATION. 2004;77(4):526-531

Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus.

Larsson K; Aschan J; Remberger M; Ringdén O; Winiarski J; Ljungman P
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):128-134

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(3):416-423

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Ringdén O; Labopin M; Gorin N-C; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet J-P; Cordonnier C; Frassoni F
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2004;190(1):239-245

Immunologic properties of human fetal mesenchymal stem cells.

Götherström C; Ringdén O; Tammik C; Zetterberg E; Westgren M; Le Blanc K
Article: BONE MARROW TRANSPLANTATION. 2004;33(1):79-85

Viridans streptococcal septicaemia in neutropenic patients: role of proinflammatory cytokines.

Ihendyane N; Sparrelid E; Wretlind B; Remberger M; Andersson J; Ljungman P; Ringdén O; Normark BH; Allen U; Low DE; Norrby-Teglund A
Article: BONE MARROW TRANSPLANTATION. 2004;33(1):47-52

Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.

Uzunel M; Ringdén O
Article: TRANSPLANTATION. 2003;76(8):1208-1213

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Rasmusson I; Ringdén O; Sundberg B; Le Blanc K
Article: BLOOD. 2003;102(8):3043-3051

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.

Gorin NC; Labopin M; Rocha V; Arcese W; Beksac M; Gluckman E; Ringden O; Ruutu T; Reiffers J; Bandini G; Falda M; Zikos P; Willemze R; Frassoni F; European Cooperative Group for Blood and Marrow Tr
Article: EXPERIMENTAL HEMATOLOGY. 2003;31(10):890-896

HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Le Blanc K; Tammik C; Rosendahl K; Zetterberg E; Ringdén O
Article: HAEMATOLOGICA. 2003;88(9):1044-1052

A low body mass index is correlated with poor survival after allogeneic stem cell transplantation.

Le Blanc K; Ringdén O; Remberger M
Article: HLA. 2003;62(3):243-250

Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation.

Schaffer M; Aldener-Cannavá A; Remberger M; Ringdén O; Olerup O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2003;122(5):788-794

Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.

Uzunel M; Jaksch M; Mattsson J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;32(4):349-354

N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;32(3):265-272

Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells.

Götherström C; Ringdén O; Westgren M; Tammik C; Le Blanc K
Article: TRANSPLANTATION. 2003;76(2):423-426

Increased levels of syndecan-1 in serum during acute graft-versus-host disease.

Seidel C; Ringdén O; Remberger M
Article: TRANSPLANTATION. 2003;76(1):204-209

In vitro studies of the role of CD3+ and CD56+ cells in fetal liver cell alloreactivity.

Lindton B; Markling L; Ringdén O; Westgren M
Article: BONE MARROW TRANSPLANTATION. 2003;32(2):217-223

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.

Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2003;121(6):874-885

Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses.

Ringdén O; Barrett AJ; Zhang M-J; Loberiza FR; Bolwell BJ; Cairo MS; Gale RP; Hale GA; Litzow MR; Martino R; Russell JA; Tiberghien P; Urbano-Ispizua A; Horowitz MM
Article: TRANSPLANTATION. 2003;75(7):1061-1066

Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans.

Söderdahl G; Barkholt L; Hentschke P; Mattsson J; Uzunel M; Ericzon B-G; Ringdén O
Article: PEDIATRIC TRANSPLANTATION. 2003;7(2):130-136

Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children.

Svennilson J; Remberger M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;31(6):429-435

The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.

Nilsson C; Aschan J; Hentschke P; Ringdén O; Ljungman P; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;31(3):175-181

Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival.

Gustafsson Jernberg A; Remberger M; Ringdén O; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 2003;31(4):253-261

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.

Hentschke P; Barkholt L; Uzunel M; Mattsson J; Wersäll P; Pisa P; Martola J; Albiin N; Wernerson A; Söderberg M; Remberger M; Thörne A; Ringdén O
Article: BLOOD. 2003;101(2):469-472

Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation.

Uzunel M; Mattsson J; Brune M; Johansson J-E; Aschan J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;31(1):23-29

Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.

Garderet L; Labopin M; Gorin NC; Polge E; Fouillard L; Ehninger GE; Ringden O; Finke J; Tura S; Frassoni F
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;57(1):11-20

Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

Le Blanc K; Tammik L; Sundberg B; Haynesworth SE; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(24):4655-4664

Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Ringdén O; Labopin M; Bacigalupo A; Arcese W; Schaefer UW; Willemze R; Koc H; Bunjes D; Gluckman E; Rocha V; Schattenberg A; Frassoni F
Article: BLOOD. 2002;100(13):4317-4324

Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care.

Svahn B-M; Remberger M; Myrbäck K-E; Holmberg K; Eriksson B; Hentschke P; Aschan J; Barkholt L; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2002;30(12):833-841

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.

Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2002;30(11):761-768

The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors.

Remberger M; Mattsson J; Hentschke P; Aschan J; Barkholt L; Svennilson J; Ljungman P; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(3):751-759

An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

Remberger M; Persson U; Hauzenberger D; Ringdén O
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;130(2):263-270

Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers.

Januszkiewicz A; Loré K; Essén P; Andersson B; McNurlan MA; Garlick PJ; Ringdén O; Andersson J; Wernerman J
Article: BLOOD. 2002;100(6):1977-1983

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.

Ruutu T; Eriksson B; Remes K; Juvonen E; Volin L; Remberger M; Parkkali T; Hägglund H; Ringdén O; Nordic Bone Marrow Transplantation Group
Article: STEM CELLS AND DEVELOPMENT. 2002;11(4):669-674

Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.

Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2002;187(2):475-482

Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency.

Westgren M; Ringdén O; Bartmann P; Bui T-H; Lindton B; Mattsson J; Uzunel M; Zetterquist H; Hansmann M
Article: BLOOD. 2002;100(2):406-414

Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn J-Y; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
Article: TRANSPLANT INFECTIOUS DISEASE. 2002;4(2):75-79

CMV retinitis after allogeneic bone marrow transplantation: a report of five cases.

Larsson K; Lönnqvist B; Ringdén O; Hedquist B; Ljungman P
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;119(1):240-249

Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT).

Björk IN; Brissac C; Remberger M; Mattsson J; Klaesson S; Ringdén O; Stewart J; Lundkvist I
Article: TRANSPLANTATION. 2002;73(6):930-936

Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors.

Hentschke P; Remberger M; Mattsson J; Barkholt L; Aschan J; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2002;29(5):391-397

Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors.

Remberger M; Storer B; Ringdén O; Anasetti C
Article: BLOOD. 2002;99(5):1572-1577

Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.

van Rood JJ; Loberiza FR; Zhang M-J; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
Article: FETAL DIAGNOSIS AND THERAPY. 2002;17(2):104-109

In vitro studies of haematopoietic colony-forming capacity of human fetal liver cells at exposure to cytotoxic and immunomodulatory drugs.

Lindton B; Markling L; Ringdén O; Westgren M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2002;8(12):674-682

Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Remberger M; Kumlien G; Aschan J; Barkholt L; Hentschke P; Ljungman P; Mattsson J; Svennilson J; Ringdén O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2002;34(5):347-350

Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.

Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustafsson-Jernberg A; Lewensohn-Fuchs I; Ringdén O
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2001;123(1):162-169

Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

Mattsson J; Uzunel M; Remberger M; Tammik L; Omazic B; Levitsky V; Zou JZ; Hentschke P; Ringdén O
Article: BLOOD. 2001;98(13):3569-3574

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Article: LEUKEMIA. 2001;15(12):1976-1985

Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation.

Mattsson J; Uzunel M; Tammik L; Aschan J; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(4):935-944

Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.

Mattsson J; Uzunel M; Brune M; Hentschke P; Barkholt L; Stierner U; Aschan J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2001;28(12):1161-1166

A graft-versus-colonic cancer effect of allogeneic stem cell transplantation.

Zetterquist H; Hentschke P; Thörne A; Wernerson A; Mattsson J; Uzunel M; Martola J; Albiin N; Aschan J; Papadogiannakis N; Ringdén O
Article: LAKARTIDNINGEN. 2001;98(45):4991-4995

[Stem cell transplantation in metastasized renal cancer].

Ringdén O; Brune M
Article: METABOLISM-CLINICAL AND EXPERIMENTAL. 2001;50(11):1308-1314

A combined stress hormone infusion decreases in vivo protein synthesis in human T lymphocytes in healthy volunteers.

Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Garlick PJ; Wernerman J
Article: BONE MARROW TRANSPLANTATION. 2001;28(7):657-664

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.

Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
Article: BLOOD. 2001;98(6):1982-1984

The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia.

Uzunel M; Mattsson J; Jaksch M; Remberger M; Ringdén O
Article: BLOOD. 2001;98(6):1739-1745

No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors.

Remberger M; Ringdén O; Blau IW; Ottinger H; Kremens B; Kiehl MG; Aschan J; Beelen DW; Basara N; Kumlien G; Fauser AA; Runde V
Article: PEDIATRIC TRANSPLANTATION. 2001;5(4):285-292

Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation.

Remberger M; Mattsson J; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(14):3406-3414

No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission.

Saarinen-Pihkala UM; Gustafsson G; Ringdén O; Heilmann C; Glomstein A; Lönnerholm G; Abrahamsson J; Bekassy AN; Schroeder H; Mellander L; Nordic Society of Pediatric Hematology and Oncolog
Article: CLINICAL NUTRITION. 2001;20(2):181-182

Determination of in vivo protein synthesis in human T lymphocytes.

Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Garlick PJ; Wernerman J
Article: BLOOD. 2001;97(6):1598-1603

Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.

Filipovich AH; Stone JV; Tomany SC; Ireland M; Kollman C; Pelz CJ; Casper JT; Cowan MJ; Edwards JR; Fasth A; Gale RP; Junker A; Kamani NR; Loechelt BJ; Pietryga DW; Ringdén O; Vowels M; Hegland J; Williams AV; Klein JP; Sobocinski KA; Rowlings PA; Horowitz MM
Article: BONE MARROW TRANSPLANTATION. 2001;27(5):479-485

Pharmacokinetics of liposomal busulphan in man.

Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Article: TRANSPLANTATION. 2001;71(3):433-439

T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation.

Mattsson J; Uzunel M; Remberger M; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2001;7(1):31-38

The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse.

Carlens S; Remberger M; Aschan J; Ringdén O
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(1):50-56

An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation.

Remberger M; Aschan J; Lönnqvist B; Carlens S; Gustafsson B; Hentschke P; Klaesson S; Mattsson J; Ljungman P; Ringdén O
Article: FETAL DIAGNOSIS AND THERAPY. 2001;16(1):26-31

Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro.

Lindton B; Tolfvenstam T; Norbeck O; Markling L; Ringdén O; Westgren M; Broliden K
Article: CLINICAL MICROBIOLOGY AND INFECTION. 2001;7 Suppl 2:68-79

Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.

Tollemar J; Klingspor L; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(4):1130-1137

Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?

Ringdén O; Labopin M; Gorin NC; Schmitz N; Schaefer UW; Prentice HG; Bergmann L; Jouet JP; Mandelli F; Blaise D; Fouillard L; Frassoni F; Acute Leukaemia Working Party of the European Grou
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(3):774-781

High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients.

Ljungman P; Wang FZ; Clark DA; Emery VC; Remberger M; Ringdén O; Linde A
Article: BONE MARROW TRANSPLANTATION. 2000;26(10):1057-1060

Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial.

Svahn BM; Bjurman B; Myrbäck KE; Aschan J; Ringdén O
Article: JOURNAL OF NEUROIMMUNOLOGY. 2000;111(1-2):210-214

MHC antigen expression in human first trimester spinal cord with implications for clinical transplantation procedures.

Akesson E; Markling L; Kjaeldgaard A; Falci S; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2000;26(7):775-779

Scintigraphic study of the major salivary glands in pediatric bone marrow transplant recipients.

Bågesund M; Richter S; Agren B; Ringdén O; Dahllöf G
Article: THERAPEUTIC DRUG MONITORING. 2000;22(4):383-385

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

Hassan M; Svensson JO; Nilsson C; Hentschke P; Al-Shurbaji A; Aschan J; Ljungman P; Ringdén O
Article: BLOOD. 2000;95(12):3996-4003

T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.

Champlin RE; Passweg JR; Zhang MJ; Rowlings PA; Pelz CJ; Atkinson KA; Barrett AJ; Cahn JY; Drobyski WR; Gale RP; Goldman JM; Gratwohl A; Gordon-Smith EC; Henslee-Downey PJ; Herzig RH; Klein JP; Marmont AM; O'Reilly RJ; Ringdén O; Slavin S; Sobocinski KA; Speck B; Weiner RS; Horowitz MM
Article: BLOOD. 2000;95(12):3702-3709

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Champlin RE; Schmitz N; Horowitz MM; Chapuis B; Chopra R; Cornelissen JJ; Gale RP; Goldman JM; Loberiza FR; Hertenstein B; Klein JP; Montserrat E; Zhang MJ; Ringdén O; Tomany SC; Rowlings PA; Van Hoef ME; Gratwohl A
Article: BLOOD. 2000;95(11):3323-3327

Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.

Barrett AJ; Ringdén O; Zhang MJ; Bashey A; Cahn JY; Cairo MS; Gale RP; Gratwohl A; Locatelli F; Martino R; Schultz KR; Tiberghien P
Article: TRANSPLANTATION. 2000;69(10):2043-2048

Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer.

Ringdén O; Söderdahl G; Mattsson J; Uzunel M; Remberger M; Hentschke P; Hägglund H; Sparrelid E; Elmhorn-Rosenborg A; Duraj F; Zetterquist H; Ericzon BG
Article: BONE MARROW TRANSPLANTATION. 2000;25(10):1059-1065

Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting.

Gustafsson A; Remberger M; Winiarski J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2000;25(10):1053-1058

The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O; Labopin M; Gorin NC; Meloni G; Blaise D; Reiffers J; Carlson K; Fouillard L; Frassoni F
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996

N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.

Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):915-924

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Article: TRANSPLANTATION. 2000;69(8):1582-1586

Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients.

Hammarström V; Pauksen K; Svensson H; Lönnqvist B; Simonsson B; Ringdén O; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2000;25(8):843-851

Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.

Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Article: FETAL DIAGNOSIS AND THERAPY. 2000;15(2):71-78

Mixed lymphocyte culture of human fetal liver cells.

Lindton B; Markling L; Ringdén O; Kjaeldgaard A; Gustafson O; Westgren M
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2000;44(2):202-209

In vivo protein synthesis of circulating human T lymphocytes does not respond to a cortisol challenge within 24 h.

Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Wernerman J; Garlick PJ
Article: LEUKEMIA. 2000;14(2):247-254

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease.

Mattsson J; Uzunel M; Remberger M; Ljungman P; Kimby E; Ringdén O; Zetterquist H
Article: BLOOD. 2000;95(3):807-814

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Article: BONE MARROW TRANSPLANTATION. 1999;24(9):1033-1035

Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients.

Hentschke P; Hägglund H; Mattsson J; Carlens S; Lönnqvist B; Ljungman P; Aschan J; Fredrikson S; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(8):831-836

A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation.

Hägglund H; Ringdén O; Oman S; Remberger M; Carlens S; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 1999;24(8):823-830

Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation.

Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(6):629-635

Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia.

Carlens S; Aschan J; Remberger M; Dilber M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(4):389-396

Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O; Labopin M; Frassoni F; Sanz G; Demeocq F; Prentice H; Cahn JY; Barbui T; Meloni G; Schaefer U; Reiffers J; Gorin N
Article: BLOOD. 1999;94(2):455-464

Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation.

Ringdén O; Remberger M; Runde V; Bornhäuser M; Blau IW; Basara N; Hölig K; Beelen DW; Hägglund H; Basu O; Ehninger G; Fauser AA
Article: BLOOD. 1999;93(7):2196-2201

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.

Ringdén O; Remberger M; Ruutu T; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Mellander L; Ljungman P; Jacobsen N
Article: BONE MARROW TRANSPLANTATION. 1999;23(6):555-560

Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries.

Schroeder H; Gustafsson G; Saarinen-Pihkala UM; Glomstein A; Jonmundsson G; Nysom K; Ringdén O; Mellander L
Article: BONE MARROW TRANSPLANTATION. 1999;23(3):283-290

Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients.

Tollemar J; Gross N; Dolgiras N; Jarstrand C; Ringdén O; Hammarström L
Article: MYCOSES. 1999;42(4):239-247

PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients.

Chryssanthou E; Klingspor L; Tollemar J; Petrini B; Larsson L; Christensson B; Ringdén O
Article: BLOOD. 1998;92(12):4568-4572

Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.

Hägglund H; Remberger M; Klaesson S; Lönnqvist B; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(11):1119-1122

Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy.

Solders G; Celsing G; Hagenfeldt L; Ljungman P; Isberg B; Ringdén O
Article: TRANSPLANTATION. 1998;66(10):1330-1334

Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.

Ljungman P; Aschan J; Lewensohn-Fuchs I; Carlens S; Larsson K; Lönnqvist B; Mattsson J; Sparrelid E; Winiarski J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(8):795-800

Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection.

Sparrelid E; Hägglund H; Remberger M; Ringdén O; Lönnqvist B; Ljungman P; Andersson J
Article: BONE MARROW TRANSPLANTATION. 1998;22(8):755-761

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.

Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Article: TRANSPLANTATION. 1998;66(5):620-625

Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.

Ringdén O; Remberger M; Carlens S; Hagglund H; Mattsson J; Aschan J; Lönnqvist B; Klaesson S; Winiarski J; Dalianis T; Olerup O; Sparrelid E; Elmhorn-Rosenborg A; Svahn BM; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 1998;22(5):499-501

Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation.

Ljungman P; Halasz R; Hägglund H; Sönnerborg A; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(2):131-136

Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow.

Hägglund H; Ringdén O; Remberger M; Lönnqvist B; Sparrelid E; Tammik L; Kumlien G
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 1998;77(6):591-593

Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia.

Eneroth E; Remberger M; Vahlne A; Ringden O
Article: BONE MARROW TRANSPLANTATION. 1998;22(1):73-78

Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation.

Remberger M; Ringdén O; Ljungman P; Hägglund H; Winiarski J; Lönnqvist B; Aschan J
Article: BONE MARROW TRANSPLANTATION. 1998;21(10):995-1003

Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.

Schmitz N; Bacigalupo A; Hasenclever D; Nagler A; Gluckman E; Clark P; Bourquelot P; Greinix H; Frickhofen N; Ringdén O; Zander A; Apperley JF; Gorin C; Borkett K; Schwab G; Goebel M; Russell NH; Gratwohl A
Article: PEDIATRIC TRANSPLANTATION. 1998;2(2):150-156

Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.

Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
Article: CLINICAL TRANSPLANTATION. 1998;12(2):84-92

Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.

Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Article: BONE MARROW TRANSPLANTATION. 1998;21(4):331-335

Intraosseous compared to intravenous infusion of allogeneic bone marrow.

Hägglund H; Ringdén O; Agren B; Wennberg L; Remberger M; Rundquist L; Svahn BM; Aspelin P
Article: BONE MARROW TRANSPLANTATION. 1998;21(1):79-84

Cadaveric bone marrow and spleen cells for transplantation.

Söderdahl G; Tammik C; Remberger M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;21(1):43-49

Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age.

Ringdén O; Remberger M; Mattsson J; Aschan J; Carlens S; Hägglund H; Lönnqvist B; Sparrelid E; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 1997;20(11):909-913

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.

Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Article: JOURNAL OF NEUROTRAUMA. 1997;14(11):875-884

Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt.

Falci S; Holtz A; Akesson E; Azizi M; Ertzgaard P; Hultling C; Kjaeldgaard A; Levi R; Ringden O; Westgren M; Lammertse D; Seiger A
Article: SUPPORTIVE CARE IN CANCER. 1997;5(6):485-488

Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study.

Ljungman P; Hägglund H; Björkstrand B; Lönnqvist B; Ringdén O
Article: PEDIATRIC TRANSPLANTATION. 1997;1(2):124-129

Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.

Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
Article: TRANSPLANTATION. 1997;64(8):1207-1208

Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis.

Hägglund H; Winiarski J; Ringdén O; Sparrelid E; Ericzon BG
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;59(4):254-262

Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver.

Remberger M; Ringdén O
Article: ORAL ONCOLOGY. 1997;33(5):327-331

Risk factors for salivary dysfunction in children 1 year after bone marrow transplantation.

Dahllöf G; Bågesund M; Remberger M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1997;20(6):479-483

Impact of conditioning regimens on salivary function, caries-associated microorganisms and dental caries in children after bone marrow transplantation. A 4-year longitudinal study.

Dahllöf G; Bågesund M; Ringdén O
Article: TRANSFUSION. 1997;37(7):678-684

Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction.

Shanwell A; Kristiansson M; Remberger M; Ringdén O
Article: ACTA PAEDIATRICA. 1997;86(5):484-492

Treatment of adrenoleukodystrophy with bone marrow transplantation.

Malm G; Ringdén O; Anvret M; von Döbeln U; Hagenfeldt L; Isberg B; Knuutila S; Nennesmo I; Winiarski J; Marcus C
Article: BONE MARROW TRANSPLANTATION. 1997;19(10):963-968

Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study.

Ringdén O; Labopin M; Gluckman E; Hows JM; Bradley BA; Kolb HJ; Fouillard L; Jacobsen N; Vernant JP; Witz F; Harousseau JL; Gorin NC
Article: BONE MARROW TRANSPLANTATION. 1997;19(9):905-908

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.

Sparrelid E; Ljungman P; Ekelöf-Andström E; Aschan J; Ringdén O; Winiarski J; Wåhlin B; Andersson J
Article: LANCET. 1997;349(9050):476

12-year follow-up of allogeneic bone-marrow transplant for Langerhans' cell histiocytosis.

Ringdén O; Lönnqvist B; Holst M
Article: BONE MARROW TRANSPLANTATION. 1997;19(3):233-236

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.

Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 1997;176(1 Pt 1):49-53

Tissue distribution of transplanted fetal liver cells in the human fetal recipient.

Westgren M; Ek S; Bui T; Jansson B; Kjaeldgaard A; Markling L; Nennesmo I; Seiger A; Sarby B; Thornström S; Ringden O
Article: LEUKEMIA & LYMPHOMA. 1996;24(1-2):71-79

The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A
Article: BONE MARROW TRANSPLANTATION. 1996;18(6):1179-1181

Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions.

Ljungman P; Lawler M; Lönnqvist B; Ringdén O; Shanwell A
Article: BONE MARROW TRANSPLANTATION. 1996;18(5):921-929

Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Article: TRANSPLANTATION. 1996;62(8):1076-1080

Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation.

Hágglund H; Ringdén O; Ericzon BG; Duraj F; Ljungman P; Lönnqvist B; Winiarski J; Tydén G
Article: FETAL DIAGNOSIS AND THERAPY. 1996;11(5):326-334

Colony formation of human fetal CD34+ hematopoietic cells.

Ek S; Markling L; Ringdén O; Kjeldgaard A; Westgren M
Article: FETAL DIAGNOSIS AND THERAPY. 1996;11(5):318-325

Cytokine stimulation of human fetal hematopoietic cells.

Ek S; Westgren M; Markling L; Kjeldgaard A; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1996;18(3):637-639

Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation.

Orlandi F; Giambona A; Messana F; Marino M; Abate I; Calzolari R; Damiani F; Jakil C; Renda M; Dieli F; Buscemi F; Westgren M; Ringden O; Maggio A
Article: BONE MARROW TRANSPLANTATION. 1996;18(2):333-337

Loss of seroreactivity against human papillomavirus (HPV) in bone marrow transplant recipients.

Lewensohn-Fuchs I; Ljungman P; Kjerrström A; Ringdén O; Dalianis T
Article: CLINICAL INFECTIOUS DISEASES. 1996;23(1):167-169

Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation.

Ljungman P; Andersson J; Aschan J; Björkstrand B; Hägglund H; Lönnqvist B; Ringdén O; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 1996;17(6):1003-1008

Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation.

Malm G; Ringdén O; Winiarski J; Gröndahl E; Uyebrant P; Eriksson U; Håkansson H; Skjeldal O; Månsson JE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(3):637-645

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Article: MYCOSES. 1996;39(5-6):185-193

Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients.

Andström EE; Ringdén O; Remberger M; Svahn BM; Tollemar J
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1996;43(5):574-582

Inhibition of immunoglobulin production in vitro by IgG and F(ab')2 fragments, but not by the Fc portion.

Klaesson S; Tammik L; Markling L; Lundkvist I; Ringdén O
Article: TRANSPLANTATION. 1996;61(8):1176-1179

Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies.

Westgren M; Ringden O; Eik-Nes S; Ek S; Anvret M; Brubakk AM; Bui TH; Giambona A; Kiserud T; Kjaeldgaard A; Maggio A; Markling L; Seiger A; Orlandi F
Article: BONE MARROW TRANSPLANTATION. 1996;17(4):583-587

Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.

Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Article: BONE MARROW TRANSPLANTATION. 1996;17(3):357-363

Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO).

Saarinen UM; Mellander L; Nysom K; Ringden O; Schroeder H; Glomstein A; Gustafsson G
Article: ACTA PAEDIATRICA. 1996;85(3):327-335

Bone marrow transplantation in children using unrelated donors at Huddinge Hospital.

Winiarski J; Ringdén O; Remberger M; Dalianis T; Ljungman P; Borgström B
Article: ACTA PAEDIATRICA. 1996;85(2):168-172

Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation.

Heurlin N; Bergström SE; Winiarski J; Ringden O; Ljungman P; Lönnqvist B; Andersson J
Article: TRANSPLANTATION. 1995;60(11):1293-1299

Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.

Remberger M; Ringdén O
Article: TRANSPLANTATION. 1995;60(11):1225-1230

Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?

Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 1995;16(6):747-753

Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.

Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
Article: TRANSPLANTATION. 1995;60(9):961-965

Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients.

Brytting M; Mousavi-Jazi M; Boström L; Larsson M; Lunderberg J; Ljungman P; Ringdén O; Sundqvist VA
Article: DRUG SAFETY. 1995;13(4):207-218

Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

Tollemar J; Ringdén O
Article: BLOOD. 1995;86(4):1614-1618

Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients.

Ljungman P; Johansson N; Aschan J; Glaumann H; Lönnqvist B; Ringdén O; Sparrelid E; Sönnerborg A; Winiarski J; Gahrton G
Article: OBSTETRICS AND GYNECOLOGY. 1995;86(2):209-213

Cytokines in fetal blood and amniotic fluid in Rh-immunized pregnancies.

Westgren M; Ek S; Remberger M; Ringden O; Stangenberg M
Article: LANCET. 1995;345(8962):1398-1402

Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation.

Hoogerbrugge PM; Brouwer OF; Bordigoni P; Ringden O; Kapaun P; Ortega JJ; O'Meara A; Cornu G; Souillet G; Frappaz D
Article: BONE MARROW TRANSPLANTATION. 1995;15(6):869-871

Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.

Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Article: BONE MARROW TRANSPLANTATION. 1995;15(4):619-625

Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings.

Ringdén O; Remberger M; Persson U; Ljungman P; Aldener A; Andström E; Aschan J; Bolme P; Dahllöf G; Dalianis T
Article: TRANSPLANTATION. 1995;59(6):864-870

Ten years' experience of bone marrow transplantation for Gaucher disease.

Ringdén O; Groth CG; Erikson A; Granqvist S; Månsson JE; Sparrelid E
Article: BONE MARROW TRANSPLANTATION. 1995;15(3):331-335

Allogeneic bone marrow transplantation for hemophagocytic lymphohistiocytosis in Sweden.

Bolme P; Henter JI; Winiarski J; Elinder G; Ljungman P; Lönnerholm G; Ringdén O
Article: CLINICAL AND DIAGNOSTIC VIROLOGY. 1995;3(2):139-153

CMV PCR monitoring in leucocytes of transplant patients.

Ehrnst A; Barkholt L; Lewensohn-Fuchs I; Ljungman P; Teodosiu O; Staland A; Ringdén O; Tydén G; Johansson B
Article: TRANSPLANTATION. 1995;59(1):45-50

Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study.

Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Article: NORDISK MEDICIN. 1995;110(12):302-304

[Theme: bone marrow transplantation. Introduction and future outlook].

Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1995;15(1):99-104

TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD.

Remberger M; Ringden O; Markling L
Show more

All other publications

Review: FRONTIERS IN IMMUNOLOGY. 2022;13:839844

Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.

Ringdén O; Moll G; Gustafsson B; Sadeghi B
Corrigendum: BONE MARROW TRANSPLANTATION. 2021;56(9):2319

Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Percival M-E; Wang H-L; Zhang M-J; Saber W; de Lima M; Litzow M; Kebriaei P; Abdel-Azim H; Adekola K; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bejanyan N; Bhatt V; Byrne M; Cahn J-Y; Castillo P; Chao N; Chhabra S; Copelan E; Cutler C; DeFilipp Z; Dias A; Diaz MA; Estey E; Farhadfar N; Frangoul HA; Freytes CO; Gale RP; Ganguly S; Gowda L; Grunwald M; Hossain N; Kamble RT; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Krem M; Lazarus HM; Lee JW; Liesveld JL; Lin R; Liu H; McGuirk J; Munker R; Murthy HS; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Passweg JR; Prestidge T; Ringdén O; Rizzieri DA; Rybka WB; Savoie ML; Schultz KR; Seo S; Sharma A; Solh M; Strair R; van der Poel M; Verdonck LF; Yared JA; Weisdorf D; Sandmaier BM
Corrigendum: HAEMATOLOGICA. 2021;106(8):2295-2296

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Lazaryan A; Dolan M; Zhang M-J; Wang H-L; Kharfan-Dabaja MA; Marks DI; Bejanyan N; Copelan E; Majhail NS; Waller EK; Chao N; Prestidge T; Nishihori T; Kebriaei P; Inamoto Y; Hamilton B; Hashmi SK; Kamble RT; Bacher U; Hildebrandt GC; Stiff PJ; McGuirk J; Aldoss I; Beitinjaneh AM; Muffly L; Vij R; Olsson RF; Byrne M; Schultz KR; Aljurf M; Seftel M; Savoie ML; Savani BN; Verdonck LF; Cairo MS; Hossain N; Bhatt VR; Frangoul HA; Abdel-Azim H; Al Malki M; Munker R; Rizzieri D; Khera N; Nakamura R; Ringdén O; Van der Poel M; Murthy HS; Liu H; Mori S; De Oliveira S; Bolaños-Meade J; Elsawy M; Barba P; Nathan S; George B; Pawarode A; Grunwald M; Agrawal V; Wang Y; Assal A; Caro PC; Kuwatsuka Y; Seo S; Ustun C; Politikos I; Lazarus HM; Saber W; Sandmaier BM; De Lima M; Litzow M; Bachanova V; Weisdorf D
Review: BLOOD REVIEWS. 2020;43:100669

Can we prevent or treat graft-versus-host disease with cellular-therapy?

Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
Editorial comment: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(2):308

Protocol Changes Lead to Lowering of SOS Rates
Review: TRENDS IN MOLECULAR MEDICINE. 2019;25(2):149-163

Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines.

Moll G; Ankrum JA; Kamhieh-Milz J; Bieback K; Ringdén O; Volk H-D; Geissler S; Reinke P
Letter: LAKARTIDNINGEN. 2016;113:DUYW

[Important that Sweden allows new treatments on vital indication].

Ringdén O
Review: LANCET HAEMATOLOGY. 2016;3(1):e45-e52

Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis.

Hashmi S; Ahmed M; Murad MH; Litzow MR; Adams RH; Ball LM; Prasad VK; Kebriaei P; Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2015;50(7):1007-1009

Bone marrow aspiration technique has deteriorated in recent years.

Remberger M; Ringdén O; Mattsson J
Letter: LANCET RESPIRATORY MEDICINE. 2015;3(4):e12

Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome.

Ringdén O
Letter: TRANSPLANTATION. 2014;98(12):e95-e96

Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease.

Maeurer M; Magalhaes I; Andersson J; Ljungman P; Sandholm E; Uhlin M; Mattsson J; Ringdén O
Editorial comment: BLOOD. 2014;124(25):3672-3673

GVHD prophylaxis made safe, easy, and inexpensive.

Ringdén O
Letter: BONE MARROW TRANSPLANTATION. 2014;49(12):1541-1542

Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation.

Hägglund H; Remberger M; Ringden O
Other: TRANSPLANTATION. 2014;98(2):122-123

In memoriam--Carl-Gustav Groth 1933-2014.

Ericzon B-G; Lundgren G; Tibell A; Tydén G; Ringdén O
Review: BONE MARROW TRANSPLANTATION. 2014;49(6):737-743

Stromal cells-are they really useful for GVHD?

Kaipe H; Erkers T; Sadeghi B; Ringdén O
Letter: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2012;96(6):822-824

Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients.

Remberger M; Ringdén O
Editorial comment: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(11):1615-1617

Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?

Ringdén O; Sadeghi B
Letter: BONE MARROW TRANSPLANTATION. 2011;46(8):1158-1160

Pooled MSCs for treatment of severe hemorrhage.

Ringdén O; Leblanc K
Editorial comment: BONE MARROW TRANSPLANTATION. 2011;46(2):163-164

Mesenchymal stromal cells as treatment for chronic GVHD.

Ringden O; Keating A
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):S287

BONE MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONORS IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Ringden O; Labopin M; Beelen DW; Volin L; Ehninger G; Finke J; Greinix HT; Kyrcz-Krzemien S; Bunjes D; Brinch L; Niederwieser D; Arnold R; Mohty M; Rocha V
Review: BRITISH JOURNAL OF HAEMATOLOGY. 2009;147(5):614-633

The allogeneic graft-versus-cancer effect.

Ringdén O; Karlsson H; Olsson R; Omazic B; Uhlin M
Meeting abstract: BLOOD. 2009;114(22):1306

Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT

Mohty M; Labopin M; Socie G; Milpied N-J; Attal M; Blaise D; Ringden O; Brown P; Lorentz B; Brune ML; Hamladji R-M; Duarte RF; Nagler A; Rocha V
Editorial comment: STEM CELLS AND DEVELOPMENT. 2009;18(9):1243-1246

Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation.

Ringdén O
Meeting abstract: HUMAN IMMUNOLOGY. 2009;70:S100

MAINTAINED TOLERANCE OF NK CELLS EXPRESSING INHIBITORY KIR FOR NON-SELF LIGANDS IN HLA-MATCHED SIBLING STEM CELL TRANSPLANTATION

Schaffer M; Bjorklund A; Fauriat C; Ringden O; Remberger M; Ljungman P; Ljunggren H-G; Malmberg K-J
Editorial comment: LANCET ONCOLOGY. 2009;10(5):440-442

Immune reconstitution after HLA mismatched haemopoietic stem-cell transplantation.

Ringdén O; Karlsson H; Omazic B
Editorial comment: PEDIATRIC TRANSPLANTATION. 2009;13(3):272-277

Pediatric transplantation: ten years on.

Benden C; Dipchand AI; Danziger-Isakov LA; Esquivel CO; Ringdén O; Wray J; Marks SD
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):85

INCREASED FREQUENCY AND RESPONSIVENESS OF PSA-SPECIFIC T CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PROSTATE CANCER

Mattsson J; Okas M; Ringden O; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):59

GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS OF HLA-IDENTICAL SIBLING TRANSPLANTS

Olsson R; Remberger M; Mattsson J; Hassan Z; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):21-22

RISKS AND BENEFITS OF UNRELATED DONOR PERIPHERAL BLOOD PROGENITOR CELL S (PBSC) IN CHILDREN AND ADOLESCENTS WITH ACUTE LEUKEMIA

Ringden O; Eapen M; Locatelli F; Champlin RE; Frangoul HA; Remberger M; Gee AP; Laughlin MJ; Rocha V
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):47

HLA MISMATCHED MSC SUPPRESS T LYMPHOCYTE ALLORESPONSES IN VITRO AND DO NOT INDUCE IMMUNOLOGICAL MEMORY IN RECIPIENTS OF MSC INFUSION

Sundin M; Barrett J; Ringden O; Uzunel M; Lonnies H; Dackland A-L; Christensson B; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):130-131

CLINICAL EXPANSION OF CORD BLOOD DERIVED T CELLS FOR USE AS DONOR LYMPHOCYTE INFUSION AFTER CORD BLOOD TRANSPLANTATION

Okas M; Gertow J; Uzunel M; Karlsson H; Uzunel M; Ringden O; Mattsson J; Ublin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):127

N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND IN VITRO

Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):47

THE IMPORTANCE OF GRAFT CELL COMPOSITION TO OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Svenberg P; Ringden O; Uzunel M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):46

TREATMENT OF THREATENING REJECTION AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITH EX VIVO EXPANDED CB DERIVED T CELLS

Uhlin M; Okas M; Gertow J; Ringden O; Mattsson J
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):114

STABLE MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD BLOOD TRANSPLANTATION

Gertow J; Berglund S; Okas M; Ringden O; Ublin M; Mattsson J
Review: LAKARTIDNINGEN. 2008;105(51-52):3731-3735

[Progress on lysosomal diseases yields hope for cure and improvement].

Malm G; von Döbeln U; Naess K; Ringdén O
Letter: BONE MARROW TRANSPLANTATION. 2008;42(11):769-771

Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.

Remberger M; Mattsson J; Svahn B-M; Ringdén O
Letter: LANCET. 2008;372(9640):716

Mesenchymal stem cells for acute graft-versus-host disease -: Reply

Le Blanc K; Fibbe W; Frassoni F; Locatelli F; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):46

CLINICAL ISOLATION AND EX VIVO CULTURING OF CORD BLOOD-DERIVED T CELLS FOR DONOR LYMPHOCYTE INFUSION

Uhlin M; Ringden O; Mattson J
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):144

MINIMAL RESIDUAL DISEASE AND CHIMERISM IN CML PATIENTS RECEIVING ALLOGENEIC TRANSPLANTS AFTER MYELOABLATIVE OR REDUCED CONDITIONING

Uzunel M; Mattsson J; Hauzenberger D; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):48-49

MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-ANTIGEN- AND VIRUS-SPECIFIC T CELLS

Karlsson H; Samarasinghe S; Ball L; Sundberg B; Lankester AC; Dazzi F; Rao K; Veys P; Le Blanc K; Ringden O; Amrolia PJ
Meeting abstract: BLOOD. 2007;110(11):327A-328A

Recent decrease in acute GVHD and increased relapse in children with leukemia receiving unrelated donor bone marrow transplants

Davies SM; Wang D; Wang T; Arora A; Ringden O; Anasetti C; Pavletic S; Casper J; MacMillan ML; Sanders J; Wall D; Kernan NA
Meeting abstract: BLOOD. 2007;110(11):2969-872A

Prospecitve quantitative PCR monitoring of allogeneic stem cell transplant (SCT) patients at high risk for EBV associated PTLD

Omar H; Hagglund H; Gustafsson-Jernberg A; Le Blanc K; Mattson J; Remberger M; Ringden O; Sparrelid E; Sundin M; Winiarski JH; Yun Z; Ljungman PT
Review: JOURNAL OF INTERNAL MEDICINE. 2007;262(5):509-525

Immunomodulation by mesenchymal stem cells and clinical experience.

Le Blanc K; Ringdén O
Editorial comment: MEDICAL ONCOLOGY. 2007;24(3):354-356

Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?

Deneberg S; Lerner R; Ljungman P; Ringden O; Hägglund H
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):97

Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation

Remberger M; Watz E; Ringden O; Mattsson J; Shanwell A; Wikman A
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):47

Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon

Ringden O; Uzunel M; Sundberg B; Lonnies L; Nava S; Gotherstrom C; Gustafsson J; Henningsohn L; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):46

Co-transplantation of mesenchymal stem cells and hematopoietic stem cells

Le Blanc K; Sundberg B; Lonnies H; Aschan J; Barkbolt L; Gustafsson B; Ringden O
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2007;97:25-60

Immunotherapy by allogeneic stem cell transplantation.

Ringdén O
Meeting abstract: BLOOD. 2006;108(11):97A

Effect of busulphan dose adjustment on regimen-related toxicity.

Hassan Z; Remberger M; Ringden O; Oberg G; Bekassy AN; Hassan M
Review: CURRENT OPINION IN IMMUNOLOGY. 2006;18(5):586-591

Mesenchymal stem cells: properties and role in clinical bone marrow transplantation.

Le Blanc K; Ringdén O
Meeting abstract: HUMAN IMMUNOLOGY. 2006;67(10):S129

KIR-HLA mismatch in T-cell replete HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia

Schaffer M; Remberger M; Ringden O; Ljunggren H-G; Malmberg K-J
Letter: BONE MARROW TRANSPLANTATION. 2006;38(4):321-322

Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases.

Ringdén O; Svenberg P; Le Blanc K; Mattsson J; Remberger M
Letter: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(6):693-694

Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells.

Ringdén O; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):126

Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single-center

Mattson J; Remberger M; Svahn BM; Svenberg P; Winiarski J; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):40

Sensitive and quantitative chimerism analysis in AML patients with real-time PCR

Svenberg P; Uzunel M; Ringdén O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):21

European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the French ITAC group and the EBMT solid tumour working party

Barkholt L; Bregni M; Remberger M; Blaise D; Peccatori J; Massenkeil G; Pedrazzoli P; Zambelli A; Bay JO; Francois S; Martino R; Bengala C; Brune M; Lenhoff S; Porcellini A; Falda M; Siena S; Demirer T; Niederwieser D; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):2

Mesenchymal stem cells for treatment of severe acute graft-versus-host disease

Ringden O; Uzunel M; Rasmusson I; Remberger ME; Sundberg B; Lonnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Meeting abstract: BLOOD. 2005;106(11):575A

A phase 3, randomized, placebo-controlled trial of Filgrastim in patients (Pts) with hematologic malignancies (HM) treated with a myeloablative conditioning regimen and allogenic bone marrow transplantation (allo BMT)

Ernst P; Bacigalupo A; Ringdén O; Ruutu T; Zander A; Kolb H; Siegert W; Strijckmans P; Zwaan F; Skacel T
Meeting abstract: BLOOD. 2005;106(11):540A

Effects of photopheresis on mononuclear cells from healthy individuals.

Kumlien G; Remberger M; Ringdén O
Review: APMIS. 2005;113(11-12):813-830

Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives.

Ringdén O; Le Blanc K
Published paper: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(24):5788-5794

Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.

Pavletic SZ; Khouri IF; Haagenson M; King RJ; Bierman PJ; Bishop MR; Carston M; Giralt S; Molina A; Copelan EA; Ringdén O; Roy V; Ballen K; Adkins DR; McCarthy P; Weisdorf D; Montserrat E; Anasetti C
Review: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(5):321-334

Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.

Le Blanc K; Ringdén O
Other: HAEMATOLOGICA. 2005;90(4):438

Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation.

Le Blanc K; Ringdén O
Published paper: MOLECULAR IMMUNOLOGY. 2005;42(4):531-534

KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation.

Malmberg K-J; Schaffer M; Ringdén O; Remberger M; Ljunggren H-G
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2):33

Transplantation after reduced intensity conditioning in patients with acute myeloid leukaemia in Sweden

Aschan J; Ringdén O; Wahlin A; Wernstedt P; Brune M
Published paper: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2 Suppl 2):17-20

Introduction to graft-versus-host disease.

Ringdén O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2):69-70

Human mesenchymal stem cells affect IgG production induced by lipopolysaccharide, cytomegalovirus and varicella zoster virus in human spleen

Rasmusson I; Sundberg B; Le Blanc K; Ringden O
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(3):649-650

Antiapoptotic effect of growth factors in leukemia -: Reply

Ringdén O
Published paper: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(24):4872-4880

Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.

Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(21):4430-4432

Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation -: In reply

Ringdén O
Letter: LEUKEMIA. 2004;18(8):1430-1433

Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.

Schmid C; Schleuning M; Aschan J; Ringdén O; Hahn J; Holler E; Hegenbart U; Niederwieser D; Dugas M; Ledderose G; Kolb H-J
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):17

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death

Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):80

Indium-III labelled donor lymphocyte infusion via hepatic artery or IV against liver metastases of renal and colon carcinoma after allogeneic haematopoietic stem cell transplantation

Barkholt L; Danielsson R; Calissendorff B; Svensson L; Malihi R; Uzunel M; Remberger M; Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2004;33(2):257-258

Urgent need for a validated tumor response evaluation system for use in immunotherapy -: Reply

Barkholt L; Hentschke P; Ringdén O
Editorial comment: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2)

Abstracts from the 2004 Tandem BMT Meetings -: American Society for Blood and Marrow Transplantation and International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry -: Introductory remarks

Ringdén O; Champlin RE; Negrin R
Editorial comment: PEDIATRIC TRANSPLANTATION. 2003;7(6):422-425

Novel treatment for refractory acute myeloid leukemia.

Ringdén O
Meeting abstract: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2003;189(6):s215

Donor chimerism across full allogenic barriers achieved by in utero transplantation of fetal mesenchymal stem cells in a case of osteogenesis imperfecta

Westgren L; Anneren G; Axelsson O; Evald U; Leblanc K; Ringden O
Editorial comment: TRANSPLANTATION. 2003;76(7):1011-1012

Transplantation of embryonic stem cells: possibilities and challenges.

Ringdén O; Le Blanc K; Hovatta O
Published paper: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(21):4324-4330

Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey.

Rocha V; Labopin M; Gluckman E; Powles R; Arcese W; Bacigalupo A; Reiffers J; Iriondo A; Ringdén O; Ruutu T; Frassoni F; Acute Leukemia Working Party of the European Blood
Letter: LANCET. 2002;359(9309):888

Survival after bone-marrow transplantation.

Remberger M; Ringdén O
Published paper: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2002;49 Suppl 1:51-55

Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital.

Ringdén O
Review: CLINICAL TRANSPLANTATION. 2001;15(3):147-153

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin.

Remberger M; Aschan J; Barkholt L; Tollemar J; Ringdén O
Published paper: TRANSPLANTATION PROCEEDINGS. 2001;33(1-2):1862-1864

An allogeneic anti-cancer effect after hematopoietic stem cell transplantation.

Barkholt L; Hentschke P; Zetterquist H; Mattsson J; Uzunel M; Wersäll P; Martola J; Albin N; Aschan J; Wijkström H; Tillegård A; Oman S; Wernerson A; Niederwieser D; Thörne A; Ringdén O
Published paper: TRANSPLANTATION PROCEEDINGS. 2001;33(1-2):1769-1770

An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation.

Remberger M; Aschan J; Lönnqvist B; Carlens S; Gustafsson B; Hentschke P; Klaesson S; Mattsson J; Ljungman P; Ringdén O
Published paper: BONE MARROW TRANSPLANTATION. 2000;25 Suppl 2:S6-S8

Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation.

Ringdén O; Remberger M; Runde V; Bornhäuser M; Blau IW; Basara N; Hölig K; Beelen DW; Hägglund H; Basu O; Ehninger G; Fauser AA
Meeting abstract: GASTROENTEROLOGY. 2000;118(4):A1414

Tumor reduction surgery followed by allogeneic stem cell transplantation. A treatment for disseminated gastrointestinal cancer?

Thorne A; Zetterquist H; Hentchke P; Mattsson J; Uzunel M; Aschan J; Ohman S; Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2000;25(3):342-343

Response to Dr furebring.

Ringden O; Tollemar J
Meeting abstract: TRANSPLANTATION. 1999;67(7):S144

Fungal prophylaxis by oral administration of bovine anti-Candida antibodies in allogeneic BMT

Tollemar J; Gross N; Torner P; Jarstrand C; Hammarstrom L; Ringdén O
Letter: BONE MARROW TRANSPLANTATION. 1998;22(7):733-734

Severe and common side-effects of amphotericin B lipid complex (Abelcet).

Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N
Letter: TRANSPLANTATION. 1998;66(1):142-143

Transplantation of peripheral blood progenitor cells from unrelated donors.

Ringdén O; Runde V; Hägglund H; Basu O; Potter M
Published paper: BONE MARROW TRANSPLANTATION. 1998;21 Suppl 3:S81-S84

Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors.

Ringdén O; Hägglund H; Runde V; Basu O; Kroschinsky F; Stockschläder M; Potter MN
Published paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3147-3149

Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia.

Carlens S; Ringdén O; Remberger M; Mattsson J; Aschan J; Hägglund H; Ljungman P
Published paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3145-3146

Transplantation with unrelated bone marrow in leukemic patients above 40 years of age.

Ringdén O; Remberger M; Mattsson J; Aschan J; Hägglund H; Carlens S; Lönnqvist B; Sparrelid E; Ljungman P
Review: MEDICAL ONCOLOGY. 1997;14(1):11-22

Bone marrow transplantation using unrelated donors for haematological malignancies.

Ringdén O
Published paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):735-736

A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate.

Mattsson J; Ringdén O; Aschan J; Barkholt L; Dalianis T; Hägglund H; Ljungman P; Lönnqvist B; Tollemar J; Winiarski J; Remberger M
Published paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):733-734

Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Published paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):714-715

Immune markers and hematopoiesis of cadaveric bone marrow for transplantation.

Söderdahl G; Tammik C; Remberger M; Sandberg J; Tufveson G; Tollemar J; Ringdén O
Review: ACTA ONCOLOGICA. 1997;36(6):549-564

Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.

Ringdén O
Review: BONE MARROW TRANSPLANTATION. 1996;18(5):831-837

In utero haematopoietic stem cell transplantation: current perspectives and future potential.

Jones DR; Bui TH; Anderson EM; Ek S; Liu D; Ringdén O; Westgren M
Letter: LANCET. 1996;348(9023):346

Graft-versus-myeloma effect.

Aschan J; Lönnqvist B; Ringdén O; Kumlien G; Gahrton G
Letter: INFECTION. 1996;24(3):269

No increase in cyclosporin neurotoxicity in transplant recipients treated with liposomal amphotericin B.

Ringdén O; Andström EE; Remberger M; Svahn BM; Tollemar J
Published paper: BONE MARROW TRANSPLANTATION. 1996;17 Suppl 2:S62-S64

Transplantation of peripheral blood progenitor cells from unrelated donors.

Ringdén O; Potter MN; Oakhill A; Cornish J; Hägglund H; Lönnqvist B; Shanwell A; Winiarski J; Pamphilon DH
Letter: BONE MARROW TRANSPLANTATION. 1995;16(6):856-857

Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease.

Ringdén O; Lönnqvist B; Hägglund H; Ljungman P; Shanwell A; Lawlor E; Schmitz N
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3536-3537

Intravenous immunoglobulin: immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients.

Klaesson S; Ringdén O; Markling L; Tammik L
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3535

No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.

Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3533-3534

Cytokines in veno-occlusive disease of the liver after bone marrow transplantation.

Remberger M; Ringdén O
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3531-3532

Bone marrow transplantation for chronic myelogenous leukemia using unrelated donors: the experience at Huddinge Hospital.

Aschan J; Ringdén O; Ljungman P; Hägglund H; Klaesson S; Dalianis T; Remberger M
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3530

Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation.

Sparrelid E; Hägglund H; Remberger M; Ljungman P; Malmborg AS; Winiarski J; Andersson J; Ringdén O
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3528-3529

Less acute GVHD in patients receiving totally matched transplants from unrelated donors.

Lönnqvist B; Ljungman P; Norrby M; Olerup O; Ringdén O; Winiarski J
Other: BONE MARROW TRANSPLANTATION. 1995;15(5):799-801

Bone marrow transplantation in two children with congenital amegakaryocytic thrombocytopenia.

Henter JI; Winiarski J; Ljungman P; Ringdén O; Ost A
Published paper: TRANSPLANTATION PROCEEDINGS. 1995;27(1):1195-1198

Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial.

Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Show more

Employments

Affiliated to Research, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2022-2025

Degrees and Education

Docent, Karolinska Institutet, 1978

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI